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1
1 INTRODUCTION 
1.1 Atherosclerosis  
Atherosclerosis is a progressive chronic inflammatory disease of the blood vessels 
characterized by the thickening of the arterial wall that becomes clinically evident 
when there is plaque rupture and thrombus formation1. It is the primary cause of 
cardiovascular diseases with enhanced mortality rate in the Western world2.  Intense 
immunological activity resulting from the interactions between modified lipids, cells of 
the immune system and of the vascular wall ultimately leads to the formation of 
lesions that protrude into the arterial lumen3. The normal human coronary artery is 
made up of endothelial cells that are exposed to blood in the arterial lumen and rest 
on a basement membrane. The tunica intima contains few smooth muscle cells 
scattered within the intimal extracellular matrix. The internal elastic lamina forms the 
barrier between the tunica intima and the underlying tunica media. The media 
consists of multiple layers of smooth muscle cells, much more tightly packed than in 
the diffusely thickened intima, and embedded in a matrix rich in elastin as well as 
collagen4 (Figure 1).  
 
 
Figure 1 A typical trilaminar structure of the human coronary artery. The endothelial barrier is exposed 
to blood flowing in the arterial lumen. An inner tunica intima with few smooth muscle cells and a tunica 
media with tightly packed smooth muscle cells separate the endothelium from the adventitia (Taken 
from Libby et al., Nature 2002).     
 
Atherosclerosis is mediated by the transport of cholesterol in the blood by LDL which 
contains a core of esterified cholesterol and triglycerides surrounded by a shell of 
phospholipids, free cholesterol and ApoB100. Particles of LDL can accumulate in the 
intima where ApoB100 binds to the proteoglycan of the extracellular matrix through 
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ionic interactions retaining the LDL particles in the subendothelial space5, 6. Several 
enzymes such as myeloperoxidases and lipoxygenases7 and some reactive oxygen 
species like HOCl and phenol radical intermediates1 have been reported to be 
involved in the modification of LDL. This initial retention of low-density lipoprotein in 
the subendothelial space and its subsequent modification triggers the activation of 
endothelial cells (ECs), which secrete chemokines such as CCL2 and macrophage 
migration inhibitory factor (MIF), and upregulate the expression of adhesion 
molecules, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule-1 (VCAM-1) and P-selectin, to recruit inflammatory cells, such as 
monocytes, granulocytes and T-cells, into the intima8, 9. In the intima, macrophage 
colony-stimulating factor (MCSF) produced by activated endothelial cells drives the 
differentiation of monocytes to macrophages which is necessary for development of 
atherosclerosis10. A hallmark of the transition from monocytes to macrophages is the 
increased expression of two major scavenger receptors: scavenger receptor class A 
(SR-A) and CD3611. These receptors bind different forms of LDL and mediate the 
uptake of modified lipids from the vessel wall. The accumulation of cholesterol 
eventually turns these macrophages to foam cells that are characteristics of early 
atherosclerotic lesion which is followed by inflammatory responses. In later stages of 
atherosclerosis there is death of large lipid-laden cells that causes the formation of a 
necrotic core which determines the stability of the atherosclerotic plaque and 
therefore is considered to be clinically important. The advanced stage of 
atherosclerosis is marked by the migration of smooth muscles cells to the 
subendothelial space where they proliferate and form connective tissues which lead 
to fibrotic cap formation (Figure 2)12.  
 
The atherosclerotic plaque is mainly composed of lipids, infiltrated immunocytes such 
as macrophages, T cells and mast cells, and a fibrous cap composed mostly of 
collagen that is formed by vascular smooth muscle cells. Fatty streak, which is an 
early lesion, consists of lipids deposited at the subendothelial space, macrophage 
foam cells loaded with cholesterol and T cells (Figure 3)1. Early lesions which are 
prevalent in young people do not cause symptoms and can either progress into 
mature atherosclerotic plaque or disappear with time13. 
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Adesion molecules  
(VCAM1, ICAM1, P-selectin)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Schematic representation of atherogenesis. Initiation of atherosclerosis is characterized by 
the activation of endothelial cells by components of modified LDL (mLDL) and possibly also by 
turbulent blood flow at arterial branching points. This induces the expression of adhesion molecules 
and secretion of chemokines. Monocytes swimming in the blood stream bind to the adhesion 
molecules and infiltrate into the subendothelial space where they are differentiated into macrophages. 
Macrophages with the help of their scavenger receptors scavenge mLDL in the vessel wall resulting in 
foam cell formation which is accompanied by inflammatory responses. Later stages involve fibrotic cap 
formation through migration and proliferation of smooth muscle cells and cell death resulting in 
necrotic core (Adapted from de Winther et al., ATVB 2005).   
 
 
A mature plaque that develops with time has a more complex structure than the early 
lesion. In the centre of a matured plaque, foam cells and extracellular lipid droplets 
form a core region that is surrounded by a fibrous cap of smooth muscle cells and a 
collagen-rich covered matrix. Other cell types present in plaques include dendritic 
cells (DCs), mast cells, a few numbers of B cells and natural killer T (NKT) cells. The 
shoulder region of a mature plaque, which is where it grows, has particularly 
abundant accumulation of macrophages and T cells, both of which are activated, 
leading to the production of a cascade of cytokines that maintain the inflammatory 
state. Concomitantly, activated smooth muscle cells (SMCs) are responsible for 
plaque growth and stability through their continued synthesis of fibrous tissue14.  
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Over time, these lesions mature and gain new characteristics which leads to the 
clinical complications of atherosclerosis4.  
 
 
 
Figure 3 Immune components of the atherosclerotic plaque. The atheroma has a core of lipids, 
including cholesterol crystals, living and apoptotic cells and a fibrous cap with smooth muscle cells 
and collagen. Plasma lipoproteins accumulate in the subendothelial region. Several types of cells of 
the immune response are present throughout the atheroma including macrophages, T cells, mast cells 
and DCs. The atheroma builds up in the intima, the innermost layer of the artery. Outside the intima, 
the media contains smooth muscle cells that regulate blood pressure and regional perfusion, and 
further abluminally, the adventitia continues into the surrounding connective tissue. Here, cells of the 
immune response accumulate outside advanced atheroma and may develop into tertiary lymphoid 
structures with germinal centers (Taken from Hansson et al., Nat. Immunol. 2011). 
 
Although these complications can already arise from stenotic lesions causing limited 
flow of blood through the arterial lumen, the most severe clinical events follow plaque 
rupture due to fibrous cap disruption, which exposes the prothrombotic material in the 
plaque to the blood and causes sudden thrombotic occlusion of the artery at the site 
of disruption. In the heart, atherosclerosis can lead to myocardial infarction (MI) and 
heart failure; whereas in the brain it can cause ischemic stroke and transient 
ischemic attacks. If atherosclerosis affects other arterial branches, it can result in 
renal impairment, hypertension, abdominal aortic aneurysms and critical limb 
ischemia. 
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Genome-wide association studies are being used to identify genes that are 
significantly associated with atherosclerotic disease and its risk factors15-17. However, 
the systematic investigation of the mechanisms underlying atherosclerosis 
development relies on animal models that show substantial overlap with the human 
disease. To generate murine models for atherosclerosis, homologous recombination 
in embryonic stem cells technique has been utilized to produce strains of mice 
lacking  apolipoprotein E (Apoe–/–), which plays a role in lipoprotein metabolism. 
These mice developed spontaneous hypercholesterolemia and atherosclerotic 
plaque which was exacerbated by an atherogenic diet18, 19. The same technology 
was used to inactivate the gene for low-density-lipoprotein receptor (LDLR). LDLR 
deficient mice (Ldlr –/–) had lower hypercholesterolemia levels when compared to the 
Apoe–/– mice and only developed atherosclerotic plaque when fed an atherogenic 
diet20. These experimental animal models have been of great help in showing that 
signs of inflammation appear hand-in-hand with incipient lipid accumulation in the 
arterial wall and contribute to each stage of atherosclerosis development. The 
recruitment of immune cells is essential for plaque formation and progression. In the 
plaque, about 40% of the cells express macrophage markers and about 10% are 
CD3+ T cells, which together with the small populations of mast cells, B cells and 
DCs, traffic between the blood, the damaged arterial wall and the regional lymph 
nodes14.  
 
1.1.1 Cellular mechanisms in atherosclerosis  
The walls of the blood vessels are composed of many constituents in addition to the 
endothelium such as matrix basement, smooth muscle cells, and pericytes. These 
components form a coherent tissue that requires, for proper function, a constant 
exchange of information via electrical and chemical signals21. A well coordinated cell-
to-cell communication is pivotal in determining whether these cells will work within 
the limits of homeostasis or induce pathogenesis of the organ in which they reside.  
 
Endothelial cell dysfunction and activation often induced by hypercholesterolemia 
and other cardiovascular risk factors, is part of the initial stages of atherosclerosis 
(Figure 4)22. The alteration of blood flow from laminar to disturbed shear stress at 
vessel branch points, bifurcations and regions of high curvature, or the accumulation 
of oxidized lipids causes ECs activation.  
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This induces a change in the expression of adhesion molecules notably, ICAM-1, 
VCAM-1, E- and P-selectin, and the synthesis of critical chemokines like CCL2, 
CXCL8, CCL5 and CCL3 that influence leukocyte recruitment23, 24. The modulation of 
the endothelial phenotype by disturbed flow requires the integration of numerous 
mechanotransduction pathways25-27. Shear-stress is transmitted from the apical 
surface of the EC through the cytoskeleton to points of attachment at cell-cell and 
cell-matrix adhesions28. Although these interactions mediate unique down-stream 
signaling, integrin and junctional signals activate common effectors that maintain a 
complex cross-talk, such as NF-κB, ERK and p38 MAPKs, Akt and Src kinases25. 
Under high shear conditions and on early atherosclerotic lesions, already adherent 
leukocytes mediate the capture of other leukocytes from the free flow. Platelets 
adhered to the vessel wall at sites of EC activation contribute largely to this 
secondary capture by releasing adhesive ligands, such as P-selectin, microparticles, 
inflammatory and mitogenic mediators into the local microenvironment, thereby 
altering the chemotactic and adhesive properties of ECs29.  
 
One of the initial responses to cholesterol accumulation in the intima is the 
expression of VCAM-1 by endothelial cells30 and its patchy distribution corresponds 
to the position at which fatty streaks will subsequently be formed31. Again, these 
regions overlap areas where endothelial cells experience disturbed flow resulting in 
impaired atheroprotective mechanisms32. The activation of ECs induces the 
recruitment of mainly monocytes and T cells3, 8, 33, but also platelets34. Platelet rolling 
is initiated by activation-dependent selectins present on endothelial and platelet 
surfaces35. MCSF produced by ECs and SMCs stimulates the differentiation of 
monocytes into macrophages and T cells become activated10, 36.  
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Figure 4 Development of atherosclerosis. A. Hyperlipidaemia and turbulent blood flow at arterial 
branching points cause endothelial-cell dysfunction and activation leading to expression of adhesion 
molecules and subsequent adhesion of platelet and leukocyte. B. Monocytes that are recruited to the 
intima and subintima differentiate into macrophages that accumulate lipids leading to the formation of 
fatty streaks. Matrix components are deposited and smooth muscle cells are recruited giving rise to 
the fibroproliferative progression of the plaque. C. Death of lipid-laden cells results in necrotic core and 
fibrous cap formation. Neovascularization can occur within the plaque and from the adventitia, and 
leakage of fragile vessels can lead to plaque haemorrhage. D. In unstable plaques, the fibrous cap 
can rupture exposing thrombogenic material leading to platelet aggregation and thrombus formation 
which is a risk for myocardial infarction (Taken from Weber et al., Nat. Immunol. 2008) 
 
Chemokines produced by vascular cells that guide the recruitment of leukocytes 
include CCL2 and its receptor CCR237, CCL8, CXCL1, CCL3, CCL4, CCL5, CXCL10 
and CXCL1138. The mast cell attractant, CCL1139, CXCL16 which can function as 
scavenger receptor or chemokine40 and CX3CL1 which is a transmembrane protein 
preferentially expressed by SMCs41 are crucial in recruiting leukocytes.    
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Monocyte extravasation is a key step in the development of atherosclerosis. Different 
subsets of monocytes are recruited into the atheromatous lesion by means of 
differentially employed CCR2, CCR5, CXCR2 and CX3CR1 chemokines42. Of note, 
circulating monocytes in the mouse exist as two equally abundant major subsets with 
differing cell surface markers and chemokine receptor expression patterns. There is 
the Ly6ChighCCR2+CX3CR1low and the Ly6ClowCCR2-CX3CR1high monocytes 
subsets43. Ly6Chigh monocytes are short-lived in the circulation and preferentially 
recruited to the inflamed tissue such as in myocardial infarction44 and in early 
atherosclerotic plaque42, 45. By contrast, Ly6Clow monocytes persist longer in the 
circulation, where they engage in so-called patrolling behavior, interacting with the 
endothelium without extravasation46. Ly6Clow monocytes show delayed incorporation 
into inflamed and damage tissues like the infarcted myocardium44. Recruitment of 
Ly6Clow monocytes into atherosclerotic plaques depends on CX3CL1 rather than 
CCL2, and their mobilization into the circulation depends on CCR542, 47. Monocytes 
swimming in the peripheral blood adhere to the surface of ECs which triggers 
monocytes gene expression programs to upregulate mandatory extravasation-
specific genes48. This initiates the differentiation of monocytes towards inflammatory 
macrophages that express a complete array of pattern recognition receptors (PRRs), 
such as scavenger receptors, CD36, CD68, CXCL16, LOX-1, SR-A and SR-BI49, 50. 
These receptors mediate the internalization of modified lipoproteins with subsequent 
cholesterol accumulation and MHC-class-II-restricted antigen presentation, and 
expression of TLRs that mediate the inflammatory response by activating NF-κB, and 
MAPK/AP1 signaling pathways51, 52.  
 
Monocytes can differentiate into two main types of macrophages: classically 
activated (M1) macrophages that promote inflammation, and M2 macrophages that 
promote resolution of inflammation53. The precursors of M1 macrophages, Ly6Chigh 
monocytes, increase in the blood during hypercholesterolemia in mice, partly due to 
their impaired conversion into less inflammatory Ly6Clow monocytes45. Models of 
inflammation have depicted the participation of Ly6Chigh monocytes in the acute 
response to inflammation, whereas Ly6Clow monocytes have been associated with 
inflammation resolution54. An imbalance in the M1/M2 ratio in the advanced stage of 
atherosclerosis therefore, may partly reflect inflammation resolution55. It is however 
worth noting that the inflammatory process in atherosclerosis is a chronic one and 
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maximal suppression of atherogenesis might require genetic manipulations that 
prevent entry of both subsets42.  Among the factors that can shift the balance in favor 
of M2 macrophage differentiation are an increase in T helper 2 (TH2) cell-secreted 
molecules, such as interleukin-4 (IL-4)53, the transcription factors peroxisome 
proliferator-activated receptor-γ (PPARγ) and PPARδ56, 57 and the bioactive lipid 
sphingosine 1-phosphate (S1P)58.  
 
Nonresolving inflammation is a key driver of atherosclerosis, and monocytes continue 
to infiltrate into subendothelial space where they differentiate into macrophages as 
atherosclerotic lesions progress. These macrophages contribute to size-independent 
changes in plaque morphology, notably formation of the necrotic core and thinning of 
the fibrous cap, which are characteristic features of a vulnerable plaque (Figure 5)59. 
Lesion complication often culminates in rupture of the fibrous cap overlying the lipid 
core. The integrity of the fibrous cap, and thus its resistance to rupture, depends 
critically on the collagenous extracellular matrix of the plaque's fibrous cap. This 
aspect of plaque structure in turn depends upon the balance between synthesis and 
degradation of the macromolecules that comprise the extracellular matrix of the cap, 
principally interstitial forms of collagen derived from arterial smooth muscle cells. 
Collagen breakdown, however, appears to depend critically on macrophages. Plaque 
macrophages express a variety of matrix-degrading enzymes that can contribute to 
the weakening of the fibrous cap (Figure 5). In this way, macrophages can critically 
influence aspects of the biology of human atheroma related to lesion stability60.  
 
Another sign of chronic inflammatory state in advanced human plaques is the 
infiltration of T cells which often accumulate at the site of atheroma rupture14. Though 
not as abundant as macrophages, T cells are recruited in parallel with macrophages 
by a similar mechanism involving adhesion molecules and chemokines1. It has been 
suggested that a first round of activation with “athero-antigens” might occur in 
regional lymph nodes after antigen presentation by DCs migrating from the plaque to 
the lymph node61. After entering the blood, previously activated memory/effector T 
cells bind to plaque-activated ECs and transmigrate into the plaque, where 
macrophages further activate them by antigen presentation3, 61.  
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Depletion of CD4+ and CD8+ T cells has been shown to reduce fatty-streak 
formation in C57BL/6 mice62. In contrast, transfer of CD4+ T cells from Apoe–/– mice 
to the severe combined immunodeficient (SCID)/ Apoe–/– mice increased the lesion 
area63.  
 
 
                                                                                         
 
 Figure 5 Macrophages in advanced atherosclerotic lesions. (1) Monocytes that are transformed into 
macrophages in the intima and subintima take up modified lipids leading to foam cell formation and 
secretion of proteases, cytokines and thrombotic factors. (2) These foam cells are not effectively 
cleared by active macrophages due to defective efferocytosis (3) leading to secondary cellular 
necrosis. (4) Secondary necrosis, over time, contributes to the formation of a necrotic core. (5) The 
fibrous cap formed by smooth muscle cells and matrix deposition weakens when proteases degrade 
the matrix and smooth muscle cells die. (6) This exposes the thrombogenic material in the lesion 
causing platelet aggregation and thrombus formation (Taken from Moore et al., Cell 2011). 
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As depicted in Figure 3, the atherosclerotic plaque is composed of several other 
immunocytes like B cells, DCs and mast cells. Neutrophils have also been shown 
and described to initiate innate immunity in atherosclerosis33. However, the detailed 
role of these cells in lesion initiation and progression will not be described in the 
context of this thesis.  
 
Atherosclerosis as already described and also shown in Figure 5 is a chronic 
inflammatory disease of the vessel wall. Monocyte-derived macrophage foam cells 
and T-cells in early fatty streak lesions contribute to sustained inflammation, driving a 
gradual progression towards more complex and eventually rupture-prone lesions1, 22. 
A key regulator of the inflammatory and immune processes associated with 
atherogenesis is the transcription factor nuclear factor-κB (NF-κB), which controls the 
expression of pro- and anti-inflammatory genes, cell proliferation and apoptosis12.  
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1.2 Nuclear factor-kappa B (NF-κB) transcription factors: regulators of complex 
biological processes 
In 1986, three proteins that showed variable nucleo-cytoplasmic subcellular 
localization were reported in a prestigious journal. These transcription factors, NF-κB, 
v-Rel and Dorsal, were shown to bind to a site of murine kappa light chain enhancer 
(κB site) stimulating its transcription in B lymphocytes64-68. These proteins were later 
demonstrated to be members of the same family of proteins. The protean nature of 
NF-κB became evident over time when it was demonstrated to be composed of two 
subfamilies: NF-κB proteins and the Rel proteins69. There is a highly conserved DNA-
binding and dimerization immunoglobulin-like domain called Rel Homology Domain 
(RHD) which is the N-terminal region of the sequence in all three Rel proteins and in 
both NF-κB proteins. In NF-κB proteins, the dimerization domain is located in the C-
terminal region of the sequence, whereas the N-terminal part of the sequence 
contains the DNA-binding domain. Close to the C-terminal end of the RHD is the 
nuclear localization signal (NLS) which is pivotal for the transport of active NF-κB 
complexes into the nucleus. Of note, the NF-κB proteins lack transactivation domain. 
The Rel subfamily includes c-Rel, RelB, RelA (p65), and Dorsal and Dif in 
Drosophila. These are characterized by a C-terminal Transcription Activation Domain 
(TAD) that is essential for positive regulation of gene expression, and which is often 
not conserved at sequence level across species. Posttranslational modification of 
both RHD and TAD eventually affect the transcriptional activity and the DNA binding 
of NF-κB.  Members of the NF-κB subfamily which are distinguished by a long C-
terminal domain that lacks TAD but compensated for by multiples of ankyrin repeats 
include p105, p100 and Drosophila Relish.  The NF-κB proteins are processed to 
shorter and active DNA-binding proteins, p105 to p50 and p100 to p52, after limited 
proteolysis or arrested translation. Unless associated with members of Rel subfamily, 
these processed NF-κB proteins may repress transcription due to the lack of TAD. 
Constitutive binding of p50 or p52 homodimers to κB sites on NF-κB responsive 
promoters may therefore act to check NF-κB transactivation until competed off by 
transcriptionally competent dimers 70 (Figure 6).   
 
In steady-state conditions, NF-κB is sequestered in the cytoplasm through 
association with one of the typical inhibitor of kappa B (IκB) proteins: IκBα, IκBβ, IκBε 
and Drosophila Cactus. There are two inducibly expressed and atypical IκB proteins, 
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BCL-3 and IκBξ, and an alternative transcript of the NF-κB1 gene that in mouse 
encodes IκBγ, whose biological function is still elusive. A characteristic feature of IκB 
proteins is the presence of multiple ankyrin repeat domains which have different 
affinities for individual NF-κB dimers (Figure 6). In mammalian cells, the three 
principal IκB proteins, IκBα, IκBβ and IκBε are regulated by phosphorylation and 
proteolysis and show differences in their tissue -specific expression patterns.  
 
Figure 6 The members of NF-κB, IκBα 
and IKK mammalian family of proteins. 
Panel A shows five NF-κB family 
members: RelA (p65), RelB, c-Rel, 
p50/p105 (NF-κB1) and p52/p100 
(NF-κB2). p50 and p52 (not shown) 
are derived from the longer precursor 
proteins p105 and p100, respectively 
in mammalian cells. All NF-κB family 
members contain an N-terminal Rel 
homology domain (RHD) that 
mediates binding and dimerization of 
DNA and a nuclear-localization 
domain. The Rel subfamily, RelA, 
RelB and c-Rel, contain C-terminal 
transcriptional activation domains 
(TADs). TA1 and TA2 are subdomains 
of the RelA transactivation domain. 
Panel B shows the inhibitor of NF-κB 
(IκB) family members consisting of 
IκBα, IκBβ, IκBε and BCL-3. Like p105 
and p100, the IκB proteins contain 
ankyrin-repeat motifs (ANK) in their C 
termini. Panel C shows the three core 
subunits of the IκB kinase (IKK) 
complex: the catalytic subunits IKKα 
and IKKβ and the regulatory subunit 
called the NF-κB essential modifier 
(NEMO, also known as IKKγ). The 
principal structural motifs of each 
protein are shown, together with 
amino-acid numbers corresponding to 
the human proteins, although some 
definitions of where a domain begins 
and ends might differ between 
publications. 
CC, coiled-coil; DD, region with 
homology to a death domain; HLH, 
helix–loop–helix; LZ, RelB-
transactivation-domain containing a 
putative leucine-zipper-like motif; 
NBD, NEMO-binding domain; PEST, 
domain rich in proline (P), glutamate 
(E), serine (S) and threonine (T); ZF, 
zinc-finger domain (Perkins ND, Nat      
                                                                                  Rev Mol Cell Biol. 2007). 
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The classical model of IκB function depicts that IκBα, the most studied member, 
retains NF-κB, mainly p65/p50 dimers, in an inactive conformation in the cytoplasm 
preventing their nuclear translocation and subsequent DNA binding. Biochemical and 
structural studies have determined that IκBα makes multiple contacts with NF-κB. 
These associations mask the nuclear localization sequence (NLS) located in the 
RHD of p65 retaining the IκBα/NF- κB complex in the cytoplasm. The crystal 
structure of IκBα bound to p65/p50 heterodimer reveals that IκBα only masks the 
NLS of p65 whereas that of p50 remains exposed. The exposed NLS of p50 acts in 
synergy with the nuclear export sequence (NES) in both IκBα and p65 to constantly 
shuttle IκBα/NF-κB complexes between the nucleus and the cytoplasm, despite 
steady-state localization that appears almost exclusively cytosolic71. The atypical IκB 
proteins, BCL3 and IκBξ, regulate NF-κB in a different but non-opposing manner. 
BCL3 has been shown to associate with p50- and p52-containing dimers. BCL3 
contains a TAD that may mediate the release of transcriptional repression by 
removing p50 homodimers from κB sites. Alternatively, BCL3 may also stabilize 
repressive p50 homodimers and inhibit NF-κB activation by preventing its access to 
κB sites72. IκBξ has weak homology to other IκBs and is more similar to BCL3. IκBξ is 
upregulated in response to IL-1 and TLR4 ligands but not TNFα. Upon expression 
IκBξ remains localized in the nucleus associated primarily with p50 homodimers and 
is required for the regulation of a subset of LPS- or IL-1-induced target genes73.    
 
A wide variety of pro-inflammatory signals trigger NF-κB activation through 
differential signaling pathways, the canonical and the non-canonical pathways, which 
all converge on the activation of the IκB kinase (IKK) complex, consisting of two 
catalytically active components (IKK1/IKKα and IKK2/IKKβ) and one regulatory 
component (IKKγ/NEMO)74. 
 
1.2.1 Differential NF-κB activation signaling cascade 
The activation of NF-κB signaling has been described for two well distinct signaling 
pathways: the canonical or the classical and the non-canonical or alternative 
pathways. The canonical pathway is activated by a wide range of inflammatory 
stimuli including pro-inflammatory cytokines such as tumor necrosis factor-α (TNFα) 
and interleukin-1 (IL-1), engagement of T-cell receptor (TCR) or exposure to bacterial 
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products such lipopolysaccharide (LPS)75 (Figure 7). These extracellular stimuli can 
activate cells through their respective receptors, which will induce the activation of a 
couple of signal transduction pathways which will all eventually converge on the 
activation of the IKK complex. This complex consists of two homologous subunits 
with kinase activity, IKK1/IKKα and IKK2/IKKβ, and a regulatory subunit IKKγ/NEMO. 
The subunits with kinase activity share 52% overall sequence identity with a greater 
degree of homology in the catalytic domain. The regulatory subunit is not related to 
the catalytic subunits and contains a C-terminal Zn finger-like domain, a leucine 
zipper and coiled-coil domains at the N and C terminus76. Although generally found in 
heteromeric kinase complex, IKKα and IKKβ are selectively required for specific NF-
κB signaling cascades. In most canonical NF-κB signaling, IKKβ is necessary and 
sufficient for phosphorylation of IκBα on serine residues 32 and 36, and of IκBβ on 
serine residues 19 and 23. This phosphorylation induces ubiquitination which is 
followed by proteasomal degradation. While not always required for IκBα 
phosphorylation and degradation in canonical NF-κB signaling, IKKα can mediate 
IκBα phosphorylation and might play a critical role in certain canonical NF-κB-
dependent transcriptional responses77.  The inducible degradation of NF-κB inhibitory 
proteins, particularly IκBα, results in a subsequent nuclear translocation of NF-κB 
transcription factors of which p50/p65 dimers are the predominant78.  
 
The non-canonical NF-κB pathway is triggered by several extracellular stimuli that 
signal through specific set of receptors including TNFR superfamily members like B-
cell-activating factor belonging to TNF family receptor BAFFR79, 80, CD4081, 
lymphotoxin β-receptor (LTβR)82 and receptor activator for nuclear factor κB 
(RANK)83. Ligand binding to these receptors results in signaling that leads to specific 
biological roles depending on the kind of ligand-receptor mediating the signaling. A 
characteristic feature of these receptors is the presence of a TRAF-binding motif 
which recruits members of the TRAF family of proteins to the receptor complex 
during ligand ligation84. The TRAFs recruited to the signaling receptor are targeted 
for degradation by cellular inhibitor of apoptosis 1 (cIAP1)-mediated ubiquination 
triggering the release and stabilization of NF-κB-inducing kinase (NIK)85. NIK, a 
central mediator of the activation of the non-canonical NF-κB pathway, is 
constitutively degraded preventing the basal activation of this pathway.  
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However upon stabilization, NIK accumulates and activates IKKα which triggers the 
phosphorylation and subsequent processing of p100 resulting in the activation of the 
non-canonical NF-κB pathway86(Figure 7). Activation of the non-canonical NF-κB 
pathway regulates specific biological processes such as lymphoid organ 
development, B cell maturation and bone metabolism87.   
 
 
 
Figure 7 Canonical and non-canonical pathways of NF-κB activation. The engagement of TNFR, IL-
1R, and TLRs by their specific ligands leads to the recruitment of TRAFs to the signaling receptor and 
subsequent activation of TAK1 in the canonical pathway or NIK in the non-canonical pathway. In the 
canonical pathway, TAK1 phosphorylates IKK in its activation loop leading to the activation of IKK 
which then phosphorylates IκBα. Phosphorylated IκBα is targeted by specific SCF-βTrCP E3 ligase 
complex inducing the proteasomal degradation of IκBα resulting in rapid and transient nuclear 
translocation of NF-κB. The non-canonical pathway relies on phosphorylation-induced processing of 
p100 which is triggered by NIK-induced activation of IKKα. Phosphorylation of p100 by IKKα targets 
p100 for ubiquination by SCF-βTrCP E3 ligase complex and sequential processing of p100 to p52. 
Dimers of p52/RelB translocate into the nucleus to participate in gene transcription (Taken from Skaug 
et al., Annu. Rev. Biochem. 2009). 
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1.2.2 Some key players in NF-κB signal transduction pathway 
Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) represent 
important signal transducers for the TNF/IL-1/Toll-like receptor (TLR) superfamily and 
with the exception of the DNA-damage response, are required for all NF-κB signaling 
pathways88. All TRAF proteins share the C-terminal TRAF domain consisting of a 
coiled-coil domain that mediates protein-protein interactions. TRAFs 2-7 have N-
terminal RING finger domains that may function as E3 ubiquitin ligases catalyzing the 
transfer of ubiquitin to target proteins. This E3 ubiquitin ligase activity plays a central 
role in the activation of the IKK complex leading to overall activation of both the 
canonical and non-canonical NF-κB signaling cascade89. In particular, TRAF6 has 
been shown to be an E3 ubiquitin ligase that catalyzes the synthesis of a unique 
polyubiquitin chain required for IKK activation90. TRAF6-catalyzed polyubiquitination 
leads to activation of TAK1 which in turn phosphorylates IKK in the activation loop 
leading to the activation of IKK91 (Figure 8A). In the non-canonical pathway, TRAF3 
regulates the activity of NIK through constitutive association which results in 
constitutive ubiquination and rapid turnover of NIK. Receptor-induced degradation or 
sequestration of TRAF3 precedes processing of p100 due to an increase in the 
steady-state amount of NIK when TRAF3 becomes a bystander92. Accumulated NIK 
activates IKKα which drives the activation of the non-canonical NF-κB pathway. 
TRAF2 has been proven to recruit the IKK complex to the activated TNF receptor 1 
(TNFR1), through interaction with the LZ motifs of IKKα and IKKβ93. Recruitment and 
subsequent activation of IKK is mediated by other key molecules of the NF-κB signal 
transduction pathway, RIPs (receptor interacting proteins), which act with TRAF 
proteins upstream of IKK94 (Figure 8B).  
 
RIPs are characterized by their conserved serine/threonine kinase domains and are 
implicated in most canonical NF-κB-TRAF-dependent and -independent pathways95, 
96
. Among the family of RIP proteins, only RIP1 has been shown to be required for 
TNFR-dependent NF-κB activation. In TNFR1 signaling, RIP1 binds to NEMO upon 
receptor stimulation and mediates IKK recruitment to the TNF receptor97. In the 
absence of RIP1, recruitment of IKK occurs through TRAF2 but does not result in 
activation of IKK93 suggesting a role for the kinase activity of RIP1 in activation of 
IKK. However, the kinase activity of RIP1 has been shown to be dispensable for the 
activation of NF-κB98.  
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There are speculations that because RIP1 is ubiquitinated during TNFR1 activation 
and TRAF2 seems to be involved in this process, TRAF2-dependent ubiquitination of 
RIP1 might be involved in the formation of a stable supramolecular complex between 
TRAF2, RIP1, and IKK. This complex will then induce the activation of IKK through 
oligomerization of NEMO and subsequent autophosphorylation of IKK99. In antigen 
receptor signaling, RIP2 is known to be required for BCL10-mediated NF-κB 
signaling100. RIP2 binds to NEMO and acts with TAK1 and TRAFs to induce NEMO-
ubiquination and down-stream signaling101, 102. Several kinases are involved in the 
signaling to IKK downstream of RIPs and TRAFs. In the canonical NF-κB pathway, 
TAK1 serves as the direct upstream kinase of IKKβ whereas in the non-canonical 
pathway NIK phosphorylates IKKα resulting in its activation.  
 
Activation of IKK in the canonical pathway is initiated by K63-linked polyubiquitination 
of IKKγ/NEMO which functions as a binding site for other signaling molecules 
required for activation of IKKβ103-105 (Figure 8A). Depending on the upstream 
signaling, different NEMO ubiquitin E3 ligases are activated causing ubiquitination at 
different lysine residues in NEMO. In TCR signaling, activation of T-cell receptor 
results in BCL10/MALT-1/Carma1-mediated TRAF6-dependent K63-linked 
ubiquitination of NEMO at lysine 399106. In response to TNFα and IL-1, TRAF6, 2 and 
5 mediate the polyubiquitination of NEMO whereas bacterial infection leads to RIP2-
dependent K63-linked polyubiquitination of IKKγ/NEMO101. Ubiquitin-based 
modifications serve to oligomerize and activate members of the IKK signaling 
pathway leading to recruitment of IKK activating kinases to the complex which will 
phosphorylate IKKs for maximal activation105.  
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A  
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Figure 8 Role of ubiquitination in the canonical NF-κB signaling cascade. A. Ligation of IL-1R and 
TLRs to their specific ligands induces the recruitment of MyD88, IRAK, and TRAF6 to the receptor. 
TRAF6 catalyzes the synthesis of K63-linked polyubiquitin chains which serve as scaffold to recruit 
TAK1 and IKK complexes thereby inducing autophosphorylation of TAK1. TAK1 in turn 
phosphorylates IKKβ leading to phosphorylation and subsequent degradation of IκBα. B. Binding of 
TNFα to TNFR, however, leads to the recruitment of TRADD, TRAF2, cIAP1 and cIAP2, and RIP1. 
TRAF2 and cIAPs mediate K63 polyubiquitination of RIP1, which recruits and activates the TAK1 
kinase complex. TAK1 phosphorylates IKK resulting in the activation of NF-κB. (Taken from Skaug et 
al., Annu. Rev. Biochem. 2009). 
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In the non-canonical pathway, TRAF3 induces ubiquitination and subsequent 
degradation of NIK but TRAF3 undergoes receptor-induced sequestration upon 
stimulation resulting in the accumulation and activation of NIK92. NIK then 
phosphorylates its direct downstream target, IKKα, at serine residues 176 and 180 
within its activation loop leading to activation of IKKα. The activation of IKK is a 
transient event that requires negative feedback regulation. Evidence exists for an 
intrinsic negative feedback loop of IKK through phosphorylation of the C-terminal 
NEMO binding domain (NBD) of IKK. Phosphorylation of NEMO at serine 68 and IKK 
NBD induces structural changes that may allow subsequent dephosphorylation of the 
activation loop serines in IKK as well as of N-terminal phosphorylation sites in NEMO 
by protein phosphatase 2A (PP2A) or PP2Cβ107-109.  
 
1.2.3 Activation and regulation of the transcription factor NF-κB  
The activation of the transcription factor NF-κB in the canonical pathway is driven by 
IKKβ-mediated phosphorylation of conserved serine residues in the three major 
cytoplasmic inhibitors of NF-κB. These inhibitory proteins, IκBα, β and ε, are then 
polyubiquitinated in a K48-linked manner by βTrCP containing Skp1-culin-
Roc1/Rbx1/Hrt-1-F-box (SCF) E3 ubiquitin ligase complexes (SCFβTrCP) which is 
followed by proteasomal degradation110. Degradation of IκBα occurs rapidly in cells 
whereas that of IκBβ and ε is delayed or does not occur111. In response to stimuli 
such as hypoxia, hydrogen peroxide and tyrosine phosphatase inhibitor pervanadate, 
IκBα is phosphorylated by tyrosine kinases. This phosphorylation of IκBα at tyrosine-
42 by putative kinases like c-Src leads to dissociation and subsequent degradation of 
IκBα110. Regulation of NF-κB inhibitory proteins represents a crucial mode of 
controlling the activation of NF-κB. Thus, these mechanisms described for IκBα 
degradation depict a way of fine-tuning NF-κB activation in the canonical pathway. 
Interestingly, there is a rapid transcription of IκBα upon NF-κB activation that serves 
as a negative feedback loop and terminates the response of NF-κB112. In the non-
canonical pathway, phosphorylation of p100 within its C-terminal domain74 creates an 
SCFβTrCP  binding site, similar to those found in IκBs. This triggers ubiquitination and 
partial proteasomal degradation of p100 with p52 as the end product113, 114. This 
mechanism for generating p52 contrasts that for p50 in the canonical pathway as p50 
is co-translationally generated in a constitutive manner. Although IKKβ-mediated 
inducible processing of p105, the precursor for p50, can occur, it often leads to 
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complete degradation of the protein without generation of p50. However, IKKβ can 
also induce SCFβTrCP-independent processing of p105 leading to the formation of 
p50115, 116. This mechanism though dependent on the ubiquitin system does not 
involve the ubiquitination of p105116. 
 
Another posttranslational modification described to affect the activity of RelA/p65 is 
acetylation117. The coactivators p300 and CBP can acetylate p65 at lysine residues 
218, 221 and 310. Acetylation of p65 at lysines 218 and 221 enhances its DNA 
binding and inhibits its association with newly synthesized IκBα whereas acetylation 
of lysine-310 activates p65 without interfering with its ability to bind DNA or IκB118. 
This way of activating p65 can be abrogated through co-repressor-mediated 
deacetylation of the acetylated residues119. In contrast, lysine residues 122 and 123 
of p65 can also be acetylated and if they do, results in decreased affinity of p65 for 
DNA binding. Phosphorylation of p65 can result in increased p300 binding to p65 that 
may lead to enhance acetylation of lysine residues in p65119, 120. Termination of NF-
κB transcriptional response has also been shown by phosphorylation of p65 at 
serine-536 by IKKα that might results in the degradation of p65121. Finally, cross-talk 
between NF-κB and other transcription factors such as PPARs122, 123, enhancer 
binding proteins-ß124, 125, AP-1126 and Janus family of kinase (Jak)-STAT127 can also 
affect the NF-κB signaling pathway. These complicated regulatory mechanisms 
contribute to the complex cellular responses of NF-κB activation.  
 
1.3 The NF-κB pathway in physiology and inflammation 
More than two decades of research in NF-κB signaling has resulted in extensive 
evidence that shows a pivotal role for this family of transcription factors in the 
immune system, cancer biology and atherogenesis. The role of NF-κB in the immune 
response is broad and expanding. It has been shown to be involved in the 
development of lymphoid organs and hematopoiesis. This extends to the elaboration 
of immediate antimicrobial responses mounted by pattern recognition receptors 
(PRRs) such as TLRs after they have recognized pathogens. There is a subsequent 
progression of inflammatory response until the elaboration of adaptive immune 
responses that can further develop into cancer128-130. Several studies using gene 
targeting and inhibitors have suggested a causative role of the transcription factor 
NF-κB in the inflammatory response.  
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Importantly, NF-κB is responsible for the transcription of genes encoding many of the 
pro-inflammatory cytokines and chemokines that orchestrate the recruitment of 
leukocytes. Expression of adhesion molecules that mediate the extravasation of 
leukocytes to the site of infection are also induced by activation of NF-κB. Numerous 
genes that regulate cellular differentiation, survival and proliferation of vascular and 
immune cells involved in inflammatory response are target of NF-κB12. NF-κB 
signaling mediates the effects of important pro-inflammatory cytokines such as TNFα 
or IL-1. There is a cross-talk between IKK/ NF-κB and interferon pathways that 
results in the release of dominant cytokines in chronic inflammatory states131. NF-κB 
is therefore crucial in the propagation of the inflammatory response and also the 
resolution that might follow. Ablation of p65 and TNFR1 in mice showed increased 
susceptibility to bacterial infection demonstrating the dependence of the early innate 
response on the canonical NF-κB pathway132.  
 
In a similar vein, IKKβ-/-/TNFR1-/- mice showed a pronounced effect in innate 
responses and succumbed to infection even more rapidly than p65-/-/TNFR1-/- mice, 
corroborating the role of the canonical NF-κB pathway in early innate response133-135. 
Inactivation of RelB in mice resulted in a complex inflammatory phenotype including 
infiltration of T cells in multiple organs and pronounced defects in hematopoiesis136, 
137
. The combined deficiency of RelB and p50 exacerbates the severity of organ 
inflammation observed in RelB knockout mice138. In a model of chronic liver disease, 
the absence of p50 homodimers in NF-κB1 knockout mice resulted in increased 
susceptibility to hepatic inflammation and fibrosis. This demonstrates the role of p50-
containing dimers in limiting inflammatory response through modulation of pro-
inflammatory gene expression such as TNFα139. The pro-survival role of NF-κB for 
hepatocytes has also been reported in NEMO-deficient hepatocytes140. Studies in 
models of liver disease have demonstrated NF-κB to constitute a link between 
chronic inflammation and cancer141, 142. A transgenic model of IKK2 overexpression in 
pancreas identified the IKK/NF-κB axis in acinar cells as being key to the 
development of experimental pancreatitis and the major factor inducing the 
inflammatory response typical of this disease143.  
 
The transcription factor NF-κB also has an active role in the resolution of 
inflammation and tissue repair144. Cells such as macrophages can become resistant 
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to repeated pro-inflammatory stimuli such as LPS. LPS tolerance involves the activity 
of BCL3 that is induced late in LPS stimulation. BCL3 acts in synergy with p50 
dimers to selectively affect chromatin remodeling of pro-inflammatory genes and also 
facilitate the expression of anti-inflammatory gene IL-10145. Of note, expression of 
IFNγ and proliferation of NK cells are negatively regulated by p50146. Importantly, it 
has been shown that inhibition of NF-κB during the resolution phase may prolong the 
inflammatory process and prevent tissue repair147. In models of local and systemic 
inflammation, genetic deletion of IKKα in macrophages resulted in increased 
production of pro-inflammatory cytokines and chemokines indicating an increased 
inflammatory response. These studies suggested that IKKα negatively regulates 
expression of these target genes through mediating the degradation of p65 and c-Rel 
following activation of macrophages by LPS121, 148. A recent study where IKKβ was 
selectively deleted in the myeloid lineage, suggested an anti-inflammatory role for 
IKKβ by inhibiting activation of macrophages through cross-talk with the Stat-1 
pathway131. This was described to prevent the overactivation of macrophages during 
infection and thereby contributing to resolution of inflammation. In an acute 
inflammatory state, activation of NF-κB mainly involves p50/p65 heterodimers which 
induces transcription through the recruitment of coactivators such CBP/p300. During 
the resolution phase of inflammation, p50 homodimers mediate transcription of anti-
inflammatory cytokines such as IL-10. Homodimers of p50 can also displace p50/p65 
heterodimers on the promoters of pro-inflammatory genes, and recruit corepressors 
such as HDAC-1 leading to repression of transcription. These concerted events 
ensure that inflammation does not persist though a more complex mechanism in 
which signaling cross-talks might have a fine-tuning modulation of the inflammatory 
response has been postulated131, 149-151.  
 
1.3.1 TNF as a promoter of the inflammatory response 
The potent pro-inflammatory cytokine TNF) is a member of the TNFR superfamily 
which consists of a number of receptors and ligands that exhibit a remarkable 
diversity in tissue distribution and physiology152. TNF is primarily produced as a type 
II transmembrane protein arranged in stable homotrimers153, 154. From this 
membrane-integrated form, the soluble homotrimeric cytokine (sTNF) is released via 
proteolytic cleavage by the metalloprotease TNF alpha converting enzyme 
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(TACE)155. The soluble 51 kDa trimeric sTNF tends to dissociate at concentrations 
below the nanomolar range, thereby losing its bioactivity152.  
The 17 kDa TNF protomers are composed of two antiparallel β-pleated sheets with 
antiparallel β-strands, forming a ‘jelly roll’ β-structure, typical for the TNF ligand 
family, but also found in viral capsid proteins156. The members of the TNF ligand 
family exert their biological functions via interaction with their cognate membrane 
receptors, comprising the TNF receptor (TNF-R) family157 . TNF family of receptors 
lack intrinsic enzymatic activity, signaling is therefore achieved by recruitment of 
intracellular adapter molecules that associate with the cytoplasmic tail of the receptor 
in a signal-dependent manner. Two receptors, TNFR1 and TNFR2, bind membrane 
integrated TNF as well as soluble TNF, but also the secreted homotrimeric molecule 
lymphotoxin-α (LTα)158, 159. TNFR1 is constitutively expressed in most tissues but the 
expression of TNFR2 is highly regulated and is restricted to immunocytes. Despite 
the variety of biological responses, TNF signaling converges on activation of NF-κB 
and AP-1. The recruitment of TNFR1 to membrane microdomains (lipid rafts) with 
subsequent assembly of a complex is necessary for signaling to NF-κB160. TNFα 
binds to TNFR1 inducing aggregation of the receptor which allows binding of TNFR-
associated death domain protein (TRADD). TRADD subsequently recruits adapter 
proteins that are necessary for the activation of IKK, p38 and JNK161 (Figure 8B and 
9). TNFR1 signaling can induce both cell death and survival, and this involves 
participation of both TNF transcription factors, NF-κB and AP-1 (Figure 9). Blocking 
NF-κB activation results in TNF becoming a potent inducer of apoptosis as indicated 
by either p65/TNFR1132 or IKKβ/TNFR1133 double knockout mice. TNF transiently 
activates both JNK and p38 with prolonged activation under apoptotic conditions162.  
TNFR2 signaling is mediated by the recruitment of TRAF adaptor proteins mainly 
TRAF1 and TRAF2 which results in the activation of kinases like IKK, MKK3 or JNK.  
This triggers the activation of TNF transcription factors that induce the expression of 
target genes important for cell survival163 (Figure 9).  
 
Although TNF receptors are differentially expressed on a wide range of cells and 
tissues, many of the proinflammatory effects of TNF can be explained on the basis of 
TNF’s effect on vascular endothelium and endothelial/leukocyte interactions. In 
response to TNF, endothelial cells promote inflammation by displaying, in a distinct 
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temporal, spatial and anatomical pattern, different combinations of adhesion 
molecules for leukocytes164-166.  
These include E-selectin, ICAM-1 and VCAM-1 which act in synergy with 
chemokines like CCL2 and CXCL8 to recruit different leukocyte populations to the 
intima independent of antigen recognition167-169. Many of the classical features of 
inflammation can be produced by local effects of TNF on endothelial cells. 
 
 
 
Figure 9 TNF signaling through TNFR1 and TNFR2 in T cells. TNF binds to its receptors, TNFR1 and 
TNFR2, triggering two separate intracellular signaling cascade. In normal T cells, binding of TNF to 
TNFR1 leads to the activation of signaling cascade that can result in apoptosis. This is not only cell 
type specific but also dependent on the state of activation of the cell and the cell cycle. In contrast, 
engagement of TNFR2 by TNF drives cell survival pathways that can lead to cell proliferation. In 
autoimmune T cells, there are defects in TNFR2 signaling pathway at different levels along the 
signaling cascade thereby dampening cell survival and proliferation effects. This forces autoimmune T 
cells to preferentially use TNFR1 signaling and the outcome is apoptosis. (Taken from Faustman et 
al., Nat Rev Drug Discov. 2010).   
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TNF-induced expression of cyclooxygenase 2 can increase endothelial cells 
production of vasodilatory PGI2 resulting in vasodilatation causing ‘rubor’ and ‘calor’ 
through increased local blood flow170. Tumor can result from TNF-mediated 
increased vascular permeability, allowing the increased trans-endothelial passage of 
fluid and macromolecules to create edema. In addition, TNF-induced expression of 
pro-coagulant proteins, such as tissue factor, and down-regulation of anticoagulant 
proteins, such as thrombomodulin TNF, can cause intravascular thrombosis171.  
    
 
1.4 The Vascular endothelium in inflammation  
The vascular endothelium is central to the cellular and molecular events that take 
place during the inflammatory response. It is the continuous non-thrombogenic 
single-cell lining of the cardiovascular system that forms an interface between the 
blood and its components on one side and the tissues and organs on the other172. 
Vascular endothelial cells (ECs) possess an innate heterogeneity, expressed by 
differences in their structure and function according to the vessel they are lining or 
tissues in which they reside. As such, major qualitative differences exist between 
macro- and micro-vascular endothelial cells173. Vascular ECs constitute a selective 
semi-permeable barrier endowed with a machinery of caveolae, coated-pits, and 
vesicles to actively sort and gate permeant molecules. ECs react to physical and 
chemical stimuli occurring in plasma and interstitial fluid, regulating the hemostasis, 
vasomotor tone, and the immune response172, 174. Endothelial cells support all the 
various phases of the inflammatory process by changing their phenotypes 
concomitantly as the inflammatory response evolves175. Three main components of 
ECs activation underlie the onset and progression of inflammation: an increase in 
local blood flow, accounting for the red color (rubor) and warmth (calor) of inflamed 
tissues; a localized leakage of plasma protein-rich-fluid into the tissue, accounting for 
the swelling (tumor) of inflamed tissues; and a localized recruitment and activation of 
circulating leukocytes. Sustained activation of ECs nevertheless leads to deleterious 
functions that contribute to the development of immune/inflammatory-mediated 
disorder diseases, such as rheumatoid arthritis, inflammatory bowel disease or 
atherosclerosis173.  
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Acute inflammation is a result of endothelial cell activation which can be divided into 
rapid responses that are independent of new gene expression, type-I activation, and 
slower responses that depend on new gene expression, type-II activation. Whereas 
type-I activation is typically mediated by ligands that bind to G protein-coupled 
receptors (GPCRs) such as histamine H1 receptors, type-II activation is mediated by 
TNFα, IL-1, and other inflammatory cytokines derived from leukocytes. Signaling 
through GPCRs leads to transient intracellular elevations of Ca2+ and activation of the 
Ras homolog (RHO) pathway, which combine to mediate the type-I activation 
response. Increased blood flow results from Ca2+-mediated release of arachidonic 
acid from membrane phosphatidylcholine and its rapid conversion to prostaglandin I2 
(PGI2), which is a muscle vascular tone. In addition, the cytosolic Ca2+-calmodulin 
complex activates endothelial nitric oxide synthase (eNOS) to produce NO, the main 
EC vasodilator that acts in concert with PGI2175. Vascular leakiness results from 
activation of myosin-light-chain kinase (MLCK) and this mediates the contraction of 
actin filaments that are attached to tight and adherens junction. This results in the 
opening of gaps between adjacent endothelial cells leading to the leakage of plasma 
proteins from the blood into the tissues. In the tissues, plasma proteins assemble into 
a provisional matrix that supports the attachment, survival and migration of 
leukocytes176.   
 
A fundamental event in inflammatory response is the recruitment of leukocytes from 
the blood to the site of injury or infection177. Leukocyte recruitment is a sequential 
cascade of events involving leukocyte and endothelial cell adhesion molecules that 
support leukocyte tethering and rolling, firm adhesion, and transendothelial migration 
under laminar shear stress178. Cell adhesion molecules synergize with chemokines to 
guide this process, and their combination specifies the recruitment of the appropriate 
leukocytes to the site of inflammation179. Additionally, the activation of myosin-light-
chain (MLC) causes the release of P-selectin from specialized secretory vessels, 
known as Weibel-Palade bodies (WPBs). Concomitantly, an endothelial-cell-derived 
acyl form of platelet activating factor (PAF) is generated which acts with P-selectin to 
initiate extravasation of neutrophils. Firm adhesion of leukocytes on the surface of 
ECs via endothelial adhesion molecules and leukocyte integrins is a key step that 
initiates intracellular signaling events that facilitate leukocyte recruitment180.  
 
                                                                                                                                             
 
28 
GPCR signaling lasts for some minutes after which the receptors become 
desensitized preventing a further stimulatory response and limiting the degree of 
neutrophils extravasation. A more sustained inflammatory response therefore 
requires a more persistent stimulation that is provided by type-II activation in 
response to inflammatory cytokines TNFα and/or IL-1, and activation of NF-κB. Like 
type-I activation, type-II response leads to increased blood flow, increased vascular 
leakage of plasma proteins and increased leukocytes recruitment at the site of 
inflammation. These effects are enhanced and more effective in type-II activation due 
to the expression of new genes. The recruitment of leukocytes is sustained due to 
prolonged synthesis of chemokines and the display of adhesion molecules on the 
surface of ECs that enhances neutrophils extravasation. Of note, ECs have the ability 
to present chemokines, synthesized by themselves or by other cells, on their surface 
through binding to proteoglycans181-183. More recent evidence suggests that 
chemokine-triggered arrest via integrin activation requires close localization among 
apical chemokines, their cell receptors and integrin adhesion molecules184. Failure of 
acute inflammation to eradicate the triggering stimulus, and especially if an adaptive 
immune response is activated by persistent stimulation, results in the inflammatory 
process evolving to a chronic form in which specialized effector cells are involved. 
ECs participate in this process by presenting antigens to circulating effector and 
memory T cells185. The vascular endothelium is therefore indeed central to the 
cellular and molecular events that take place during inflammatory response.  
 
1.5 Inflammatory mechanisms drive atherosclerosis   
Inflammatory mechanisms play a crucial role in all stages of atherosclerosis: from 
early endothelial activation by modified lipids to the eventual rupture of the 
atherosclerotic plaque1, 4. The activation of the canonical NF-κB signal transduction 
pathway, mediated by the phosphorylation and degradation of its inhibitory protein 
IκBα by the IκB-Kinase (IKK) complex as previously described, is a central step in 
pro-inflammatory target gene expression such as that of chemokines or adhesion 
molecules, which have been strongly implicated in atherosclerosis186. Knockout and 
transgenic models of the NF-κB signal transduction pathway have provided much 
evidence on the role of NF-κB in atherogenic inflammation. Several years after 
demonstrating the presence of activated NF-κB in human atherosclerotic lesions 
using an antibody specifically recognizing phosphorylated p65 in smooth muscle 
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cells, macrophages, and endothelial cells187, Kanters and colleagues surprisingly 
showed that, the inhibition of NF-κB activation in macrophages increases 
atherosclerosis in LDL-receptor-deficient mice188. This they showed by 
transplantation of bone marrow from mice that specifically lack IKKβ in macrophages 
into LDLR-/- mice and observed an increased in the size of atherosclerotic lesion with 
enhanced inflammation in the lesion. The authors attributed the increase in 
atherosclerotic lesion to the reduced levels of IL-10 observed when IKKβ was deleted 
in macrophages because absence of IL-10 accelerates atherosclerosis189. Studies 
using bone marrow from p50-defficient mice transplanted into an LDLR-/- mice 
showed a reduction in lesion size with a distinct plaque phenotype, characterized by 
reduced foam and immune cells190. Coherently, they observed an increased IL-10 
levels in the p50-depleted macrophages which may account for the small lesion size. 
There is therefore a complex role of the canonical NF-κB pathway in atherogenic 
inflammation which seems to be cell type-specific (endothelial cells versus 
macrophages) leading to regulation of different genes.  
 
Several in vitro studies have confirmed the role of the canonical NF-κB pathway in 
atherogenic inflammation by regulating the expression of different target genes that 
have been strongly implicated in the events in atherogenesis. NF-κB not only 
regulates a number of enzymes demonstrated to be crucial in the modification of LDL 
and the formation of inflammatory lipid mediators such as 5-lipoxygenase, 12-
lipoxygenase7 and COX2191 but also, chemokines like CCL2192 and adhesion 
molecules like ICAM-1, VCAM-1, P-selectin and E-selectin193-195. Activation of NF-κB 
also mediates the transcription of genes like tissue factor and MMPs that have 
plaque thrombotic potential196. Evidence exists for the critical role of NF-κB in smooth 
muscle cell proliferation and viability by regulating genes with survival functions. 
Using a balloon injury model in the rat carotid artery, low levels of constitutively 
activated p50, p65 and c-Rel were shown in normal vessels, a reduction in the levels 
of ΙκBα and IκBβ and a subsequent expression of VCAM-1 and CCL2 were observed. 
An antisense oligo against p65 inhibited SMC proliferation and intimal formation in rat 
carotid arteries. More recently, IκBα-expressing adenovirus applied in a rabbit iliac 
artery restenosis model, showed a reduction of ICAM-1 and CCL2 expression, 
impaired recruitment of macrophages and a narrowing of the lumen without affecting 
intimal thickness197-199.  
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Taken together, data from different models are inconsistent, indicating that the 
underlying mechanisms by which NF-κB modulates the complex events in 
atherogenic inflammation needs further investigation.  
 
The transcription factor NF-κB is subjected to a good number of control mechanisms 
as previously described. Briefly, there is, among other regulatory mechanisms, an 
auto-feedback regulation of NF-κB by its inhibitor ΙκBα, which gets rapidly transcribed 
upon binding of NF-κB to DNA, deactivating the activated transcription factor112. The 
inhibitory protein, ΙκBα, is also regulated by a SCF-type cullin-RING E3 ligase (CRL)-
driven ubiquitination process, which in turn is controlled by the COP9 signalosome 
complex (CSN)200.  
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1.6 The COP9 signalosome (CSN) complex 
The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) complex was 
first identified in Arabidopsis as an essential regulator of photomorphogenesis201. 
This conclusion was drawn when researchers were screening the plant, Arabidopsis 
thaliana for mutants that exhibit light-grown seedling characteristics. They realized 
that the CSN represses photomorphogenesis leading to dark-grown growth patterns 
and that light signals transduced from photoreceptors lead to a release of this 
repression (Figure 8).  
 
 
 
Figure 10 Model of COP9 signalosome (CSN) function in photomorphogenesis. In the absence of light 
signals, the CSN represses photomorphogenesis (light) leading to dark-grown (dark) growth patterns 
(wt, left) (Taken from Chamovitz et al., EMBO Rep. 2001). 
 
This protein complex was rediscovered some few years later during the purification of 
proteasomes from mammalian red blood cells202 as well as purified from the spleen 
of pigs203. This indicated that the function of the CSN was not limited to control of 
plant photomorphogenesis. CSN fractionates as a 450–550-kDa complex in gel 
filtration columns and further work revealed eight subunits of the complex. These 
subunits were designated as CSN1 to CSN8 depending on their sizes, from the 
largest, CSN1, to the smallest, CSN8204. The first architecture of the CSN was 
revealed by electron microscopy (Figure 9) and subunit-subunit interaction studies. 
Each subunit was linked to a corresponding subunit in the 19S lid subcomplex 
(Figure 9) of the 26S proteasome due to sequence homology205.  Since its discovery 
in plants and mammals, the COP9 signalosome complex has been identified in a 
variety of different eukaryotic organisms.  
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This includes Saccharomyces cerevisiae206, 207, Schizosaccharomyces pombe208, 
Aspergillus nidulans209, Neurospora crassa210, Caenorhabditis elegans211, and 
Drosophila melanogaster212. The range of biological responses in which the CSN is 
involved is extensive, from embryonic development, the cell cycle, checkpoint 
control, T-cell development, signal transduction, oocyte maturation, to autophagy and 
circadian rhythm, reflecting the multifunctionality of the complex213.  
 
                  
 
Figure 11 2D electron microscopic images of the CSN and the 19S LID subcomplex of the 26S 
proteasome. The putative subunit arrangement of the CSN on the basis of the subunit-subunit 
interaction studies205 is indicated. LID subunit-subunit interactions were deduced from CSN data by 
arranging homologous subunits. The central groove is marked by black arrow. (Taken from Bech-
Otschir et al., J Cell Sci. 2002) 
 
A characteristic feature of the CSN is the presence of two signature domains: a PCI 
domain that resides at the C-terminus and which is present in six subunits and an 
MPN domain that is found at the N-terminus and is present in two subunits, CSN5 
and CSN6214. The PCI domain has been shown to be composed of two subdomains: 
a winged-helix subdomain at the C-terminus, and a helix bundle subdomain at the N-
terminus (Figure 10)215-217. Proteins that bind DNA/RNA have a winged-helix domain 
which has triggered speculations that the CSN might even bind nucleic acids217.  
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Figure 12 Structures of the CSN7 PCI Domain and the MPN Domain of CSN. (A) and (B) Cartoon (A) 
and topology depictions (B) of the CSN7 PCI domain. The 1.5 A° resolution structure of CSN7’s PCI 
domain reveals two subdomains: the HB subdomain (blue) and the WH subdomain of CSN (red). α, α′, 
and β denote α-helix, 310 helix, and β strand, respectively. (C) Shows the MPN domain with its Zn 
atom (Taken from Dessau et al., The Plant Cell 2008).  
 
The subunits of the CSN were identified to either interact with each other (Figure 11) 
or independently with several signaling molecules though not all of these interactions 
have been verified by several techniques (Table 1). The fifth mammalian subunit, 
CSN5, was first identified as Jun-activation-domain-binding protein (JAB1) because 
of its interaction with the activation domain of c-Jun. JAB1/CSN5 was found to 
stabilize complexes of the transcription factors c-Jun or JunD at their specific AP-1 
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transcription factor binding sites, increasing the specificity of target gene 
activation218.  
 
 
 
 
 
Figure 13 Subunit-subunit interaction of the human CSN complex. These interactions were generated 
through integration of mass spectrometry (MS) and tandem MS data using the algorithm SUMMIT. 
Depicted on the left side are two subunit clusters: CSN1,2,3,8 and CSN4,5,6,7; interaction between 
CSN1 and 6 links the two clusters. Shown on the right side are the subunit-subunit interactions (Taken 
from Sharon et al., Structure 2009). 
 
 
 
Table 1 Binding partners of the CSN subunits 
 
 
CSN subunit Binding partner                                                               Method used in 
Analysis 
Reference 
CSN1 Inositol 1,3,4-triphosphate 5/6 kinase                               rip, eip Sun et al. 2002 
  eIF3c/NIP1, subunit of translation initiation factor 3 Y2H Karniol et al. 1998 
  RPN6 (AtS9), proteasome lid non-ATPase subunit Y2H Kwok et al. 1999 
 
 
CSN2 
ICSBP, interferon consensus sequence binding 
protein 
pd, rip Cohen et al. 2000 
  Cullin 1 (CUL1), SCF complex core component ms, Y2H Lyapina et al. 2001, 
    
IκBα  
rip Schwechheimer et al. 2001, 
Schweitzer, et al. 2007  
  Cullin 2 (CUL2) Y2H, rip Yang et al. 2002 
  DAX-1, COUP-TF1, ecdysone receptor, Y2H, pd, rip Dressel et al. 1999, 
  (nuclear receptors)  Altincicek et al. 2000 
  TR, thyroid hormones receptor Y2H, pd Lee et al. 1995 
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CSN3 
IKKγ, IKK complex  Y2H, FRET, rip, 
eip 
Hong et al. 2001, Orel et.al. 
2010 
  COP10, ubiquitin-conjugating enzyme variant Y2H Suzuki et al. 2002 
  Int-6/eIF3e, subunit of translation initiation factor 3,  
CK2, PKD 
rip, eip H. Alves et al. 2002, Uhle 
et.al. 2003 
 
CSN4 
COP10, ubiquitin-conjugating enzyme variant Y2H Suzuki et al. 2002 
 
CSN5 
c-Jun transcription activation domain, JunD                    Y2H Claret et al. 1996 
  p27kip1, cyclin-dependent kinase inhibitor                        Y2H, pd, rip Tomoda et al. 1999 
  Bcl3, member of the IκB multigene family                        Y2H, pd, rip Dechend et al. 1999 
  LFA-1, integrin adhesion receptor                                   Y2H, pd, rip, eip Bianchi et al. 2000 
  rLHR, lutropin receptor precursor                                    Y2H, pd, rip Li et al. 2000 
  MIF, chemokine-like function chemokines                        Y2H, pd, rip, eip Kleemann et al. 2000 
  PR, progesterone receptor and SRC-1                   Y2H, pd 
 
Chauchereau et al. 2000 
  p53, tumor suppressor pd Bech-Otschir et al. 2001 
  HIF-1α, hypoxia-inducible factor-1 Y2H, pd, eip Bae et al. 2002 
  Smad4, TGF-β signal transducer Y2H, pd, rip, eip Wan et al. 2002 
  HPO, hepatopoietin Y2H, pd, rip, eip Lu et al. 2002 
  TRC8, RING-finger membrane protein pd, rip Gemmill et al. 2002 
  PGP9.5, member of ubiquitin C-terminal hydrolase Y2H, eip Caballero et al. 2002 
  GLHs, germ-line RNA helicases Y2H, pd 
 
Smith et al. 2002 
 
 
 
 
Smad5, a major intracellular mediator of BMP 
Signaling 
Smad 7, TGF-β signal transducer 
 
Y2H, rip 
 
 
Y2H, pd, rip 
Aigner and Haag, 2006 
 
Kim et al. 2004 
 
 IKK complex 
 
Y2H, FRET, rip, 
eip 
Orel et al. 2010 
 
 Vpr, HIV-1 protein Y2H, pd 
 
Mahalingam et al. 1998 
 Rbx1/Roc1/Hrt1, SCF RING protein component ms, Y2H Lyapina et al. 2001, 
     Schwechheimer et al. 2001 
CSN6 
 
Int-6/eIF3e, subunit of translation initiation factor 3 rip, eip H. Alves et al. 2002 
  CSN7 Int-6/eIF3e, subunit of translation initiation factor 3 rip, eip H. Alves et al. 2002, 
  IKK complex Y2H, FRET, rip, 
eip 
 Yahalom et al. 2001,  
Orel et al. 2010 
 PMF-1, polyamine-modulated factor Y2H Y. Wang et al. 2002 
CSN8 eIF3c/NIP1, subunit of translation initiation factor 3 Y2H Karniol et al. 1998 
  COP10, ubiquitin-conjugating enzyme variant Y2H Suzuki et al. 2002 
 
Y2H, yeast two hybrid; pd, in vitro pull down assay; rip, coimmunoprecipitation with overexpressed constructs; eip, endogenous 
coimmunoprecipitation; FRET, fluorescence resonance energy transfer; ms, mass spectrometry 
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Later, JAB1/CSN5 was repeatedly found to be an interactor of various intracellular 
regulators (Table 1). Another common theme of possible significance is the frequent 
occurrence of interactions between CSN5 and its partner proteins in the context of 
multi-protein complexes, and the apparent connection of these interactions to 
ubiquitin-dependent protein degradation pathways. The N-terminus of CSN5 contains 
an MPN domain which has an intrinsic JAMM (JAB1 MPN domain metalloenzyme) 
motif that serves as the catalytic center for CSN isopeptidase activity. This JAMM 
motif can coordinate a Zn2+ atom, which is a cofactor critical for enzymatic activity219, 
220
. A well-described enzymatic activity of the CSN is the cleavage of ubiquitin-like 
Nedd8 conjugates from the cullin subunit of CRLs, including SCF-type CRLs200.  
 
1.6.1 CSN as a cullin deneddylase  
Among the different ubiquitin ligases, CRL form the largest family and the cullin 
subunit in CRLs are post-translationally modified by covalent conjugation with the 
ubiquitin-like modifier Nedd8/Rub1221. This modification is crucial for the enzymatic 
activity of CRLs. CSN catalyzes the reaction to remove Nedd8 conjugates from cullin 
a process termed deneddylation, and subsequently regulates the activity of CRLs. 
This deneddylation activity is catalyzed by the JAMM motif of CSN5, which is the only 
CSN subunit with known catalytic activity; however this enzymatic activity requires 
the entire CSN holocomplex200. The alternate conjugation and removal of Nedd8 
facilitates the dynamic assembly and disassembly of the SCF core complex with a 
substrate-binding module containing adaptor protein and substrate receptor (Figure 
12)222, 223. This may regulate the availability of SCFs for ubiquitination-induced 
proteasomal degradation of different substrates, as p27224, 225 and ΙκBα226, depending 
on the cellular needs. Whereas neddylation is required for an optimal ubiquitin ligase 
activity of SCFs227-230, CSN-mediated deneddylation has been linked with the 
dissociation of the substrate-binding module from the SCF complex223 and with the 
inhibition of SCF-mediated substrate ubiquitination in vitro231, 232. However, as SCFs 
trigger their self-inactivation through auto-ubiquitination223, dynamic dissociation and 
reassembly of the SCF with non-ubiquitinated components is a prerequisite for an 
efficient function of the SCF, which explains the requirement of the CSN for 
sustained SCF activity in vivo233-238.  
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The association of the CSN complex with ubiquitin depolymerization activity through 
its interaction with the deubiquitylase enzyme Ubp12p/USP15 in yeast239 and 
mammalian cells240, 241, respectively, has been shown to contribute to prevent 
excessive auto-ubiquitination and degradation of SCF subunits239, 241.  
  
 
 
Figure 14 The CRL family of ubiquitin ligases and its regulation by the CSN. (a) The CRL superfamily 
of ubiquitin ligases is characterized by an enzymatic core that contains a cullin family member (light 
green) and RBX1 (dark green), a RING protein. Specific substrates (light blue) are recruited to the 
core by a substrate-binding module consisting of an adaptor protein (or domains; blue) and various 
substrate receptors (turquoise). (b) Cullin neddylation enables the assembly of an active CRL, 
whereas deneddylation by CSN (light brown) facilitates the dissociation of the substrate-binding 
module and the association of CAND1 (beige) with the core complex. Color code: E2, gray; ubiquitin 
(Ub), sky blue; Nedd8 (N), yellow (Taken from Wei, N. et al., Trends Biochem. Sci. 2008). 
 
Similarly, ΙκBα242 and BCL10243, important signaling molecules in the antigen 
receptor signaling pathway to IKK/NF-κB, are stabilized through CSN-mediated 
deubiquitination in response to tumor necrosis factor (TNF)-α administration and T-
cell receptor stimulation, respectively.  
 
In addition to the CSN, it has been shown that deneddylase 1 (DEN1) exhibits 
deneddylating activity244, 245. However, DEN1 and the CSN seem to have different 
roles. Whereas DEN1 seems to function predominantly as a Nedd8 C-terminal 
hydrolase, the CSN has been proven to be the key factor that determines the rate of 
deneddylation of cullins233, 244, 246-248.  
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1.6.2 CSN5 as a protean subunit of the CSN complex  
The gene that encodes for CSN5/JAB1 is highly conserved and has been extensively 
studied in mice. Whereas the murine Csn5 gene is located on chromosome 2, the 
human CSN5 gene is located on chromosome 8 (Figure 13)249. The human CSN5 
protein consists of 334 amino acids and has a molecular mass of 38 kDa (Figure 
11A, B). While there are two Arabidopsis CSN5 homologue genes, AJH1 and AJH2, 
there is only one known isoform in humans250. CSN5 is evolutionarily conserved in 
humans, mice, fission yeast, and plants, providing evidence that CSN5 is critical for 
cell survival and proliferation202, 203, 251.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 Structure of the CSN5 gene and domains of the CSN5 protein. (A) Schematic of the CSN5 
gene which is 33 kb long and localized at chromosome 8Q13.2. (B) The 8 exons within the 334 amino 
acid sequence are shown. (C) Schematic of CSN5 protein which consists of 334 amino acids with a 
JAB1/MPN domain metalloenzyme (JAMM)-containing Mpr1-Pad1-N-terminal (MPN) domain and a 
nuclear export signal (NES) domain close to the p27 binding domain (PBD) at the C-terminal end 
(Modified after Shackleford et al., Cell Div. 2010). 
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Although all the eight subunits of the CSN complex have important roles in the 
overall function of the complex, CSN5 is unique. CSN5 does not only harbor the 
catalytic center for CSN isopeptidase activity as previously described but can also 
exist stably and independently of the CSN holocomplex213. Of note, several reports 
indicate that, depleting cellular CSN5 levels reduces monomeric CSN5 levels more 
dramatically than the CSN holocomplex. Inversely, transient overexpression of CSN5 
in cultured cells usually leads to an increase in the levels of CSN5 monomers with 
little effect on CSN holocomplex238, 252, 253. Whereas CSN-associated CSN5 is located 
primarily in the nucleus, monomeric CSN5 can be both cytoplasmic and nuclear254, 
255
. It is now clear that CSN5 actively participates in crucial biological processes, both 
as part of the CSN holocomplex and independently of the CSN. Interestingly, recent 
reports indicate that the JAMM domain of CSN5 also has deubiquitinase activity, 
which regulates ubiquitinated protein sorting into exosomes when CSN5 is 
associated with the CSN256. This links the CSN with the regulation of ubiquitinated 
proteins that are transferred by exosomes, a process that impacts the flow of 
information from neighboring or distant cells.  
 
CSN5 has numerous binding partners which include important cellular regulators 
(Table 1). Depending on the specific target, CSN5 either induces degradation or 
enhances stability of these target proteins238, 253, 257. CSN5 directly interacts with p27 
thereby controlling the cell cycle. Binding of p27 to CSN5 leads to cell cycle 
progression and the concomitant export of p27 from the nucleus and subsequent 
degradation258. The nuclear to cytoplasmic shuttling of p27, induced by CSN5, plays 
an important role in the regulation and function of p27. Accumulation of cytoplasmic 
p27 results in increased cell motility and migration through its interaction with RhoA, 
a GTPase that regulates cell motility by reorganization of actin filaments259, 260. 
Therefore the role of CSN5 in p27 cellular localization interrupts the inhibitory effect 
of p27 on cellular proliferation and also puts it in position to interact with RhoA to 
mediate cell motility and migration which has an overall tumorigenic effect on the cell. 
This effect involves the nuclear-cytoplasmic translocation of CSN5. The subcellular 
redistribution of CSN5 is a recurring theme, as CSN5 also appears to function at the 
plasma membrane261. In normal COS7 cells, transiently expressed CSN5 maintains a 
diffuse distribution. In experiments in which these cells also transiently express the 
adhesion receptor LFA-1, a fraction of CSN5 was enriched in the same peripheral 
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membrane regions as this ectopically expressed integrin, consistent with an integrin–
CSN5 interaction that had been found using the yeast two-hybrid assay261. As the 
CSN has never been shown to localize to peripheral membranes, it can be assumed 
that this form of CSN5, is CSN-independent262.  
 
CSN5, initially identified as a coactivator of c-Jun, can specifically stabilize the 
protein-DNA complexes on the off-rate of c-Jun and JunD with its cognate AP-1 DNA 
binding sites and potentiates c-Jun transactivation without affecting JunB or v-Jun 
binding. This offers a mechanism of specificity in the binding of c-Jun to target 
genes249. CSN5, through its interaction with c-Jun, is involved in c-Jun-induced AP-1-
mediated transcriptional activation and also affect the interaction between c-Jun and 
other interacting proteins. CSN5 affects other proteins and their interaction with c-Jun 
by binding directly to and changing their subcellular localization. This is true for the 
following proteins and in general lead to activation of AP-1: LFA-1261, 263, MIF258, 
hepatopoietin264, and hepatitis B virus X (HBX)265. In addition to c-Jun, CSN5 has 
been shown to be a transcriptional coactivator and potential specificity factor for 
several other molecules like NF-κB. CSN5 has been shown to interact with the proto-
oncogene BCL3, a member of the IκB family of inhibitory proteins and is present 
predominantly in the nucleus. Most members of the IκB family of inhibitory proteins 
act to inhibit NF-κB; however, BCL3 can activate the transcription of NF-κB. Binding 
of CSN5 to BCL3 leads to enhanced NF-κB, p50, and DNA complex formation and 
may link NF-κB and AP-1 gene transcription266. CSN5 also bridges coactivators and 
receptors in the progesterone receptor-steroid receptor coactivator complex (Table 
1). These studies provide evidence of the role of CSN5 as specificity factor with less 
defined mechanisms by which it acts.  
 
1.6.3 CSN-associated protein kinase activity and deubiquitinylation activity 
Purification of the CSN complex from red blood cells led to the finding that the CSN 
has an associated serine/threonine kinase activity. The CSN preparation was found 
to phosphorylate c-Jun (Ser63 and Ser73), IκBα, and the NF-κB precursor, p105, as 
well as tumor suppressor p53 (Ser149, Thr 150, and Thr 155) in vitro202, 267. This 
CSN-associated kinase activity was however shown to be inhibited by curcumin, a 
dietary pigment with known pleiotropic properties of antioxidation, anti-inflammation, 
and anti-carcinogenesis.  
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Whereas CSN-mediated phosphorylation targets p53 for degradation by the 
ubiquitin-26S proteasome system267, that of c-Jun is believed to stabilize the 
molecule and contribute to the JNK-independent activation of AP-1268. In both cases, 
CSN5, which binds to amino acids 31–57 of c-Jun218 and 1–154 of p53267, might 
serve as a substrate docking site. Another CSN-associated kinase found is the 
inositol 1, 3, 4-trisphosphate 5/6-kinase (5/6 kinase). The 5/6 kinase phosphorylates 
inositol 1,3,4-triphosphate [Ins(1,3,4)P3] to form Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4. 
The 5/6 kinase is also conserved from plants to humans. This enzyme co-purifies 
with the entire CSN complex from calf brain and directly interacts with the CSN1 
subunit. The 5/6 kinase displays substrate spectrum and characteristics similar to the 
described CSN-associated kinase purified from red blood cells. It phosphorylates c-
Jun, IκBα, ATF-2, and p53, but not c-Jun (1-79), and it is inhibited by curcumin269, 270. 
CSN itself is a target of phosphorylation, since a number of its subunits have been 
shown to be phosphorylated214, 271.  
 
Another biochemical activity that has been reported for CSN is the CSN-associated 
deubiquitinylation activity. This activity can be classified as either deconjugation of 
ubiquitin from mono-ubiquitinated substrates or depolymerization of polyubiquitin 
chains240. Whereas deconjugation of ubiquitin from mono-ubiquitinated substrates 
requires the JAMM motif in CSN5, depolymerization is associated with the CSN 
holocomplex. Collectively, these indicate that CSN has both deneddylation and 
deubiquitinylation activities either by possessing these activities on their own or by 
selectively recruiting different enzymes based on cellular needs.  
 
1.6.4 CSN’s cellular functions 
The biochemical activities reported for CSN alongside its association with the 26S 
proteasome, places CSN in a position which renders it capable of determining the 
fate of proteins to which it binds. Based on this notion, the CSN would either 
sensitize or desensitize proteins towards the ubiquitin-proteasome pathway 
(UPP).The CSN has been shown to negatively regulate G1-S phase cell cycle 
progression by desensitizing p27 towards the UPP. This effect of the CSN was linked 
to the deneddylase activity that resides in the JAMM motif at the N-terminus of 
CSN5, which is only functional in the context of the CSN holocomplex, as anti-CSN2 
antibodies nullified this CSN-dependent p27 stabilization and G1-S blockade232.  
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In a rat model of intimal hyperplasia, an adenovirus expressing a dominant-negative 
form of IκBα inhibited intimal hyperplasia in vivo and the proliferation of smooth 
muscle cells in vitro. This in vitro retardation of SMC proliferation was linked to the 
observation that the cyclin-dependent kinase inhibitor p27 was upregulated272. The 
proliferation of SMC in atherosclerosis, may mediate cap formation which is critical in 
plaque-stabilizing process. Hence, any effort to drive the proliferation of SMC will be 
a step in the right direction in stable plaque formation, and the interplay between p27 
and CSN might be of interest for further investigation. CSN also works as a positive 
regulator of AP-1 activity by stabilizing c-Jun through the phosphorylation of c-Jun by 
CSN-associated kinases like CK2 and PKD.  While CSN-dependent phosphorylation 
appears to desensitize c-Jun, an opposite effect is exerted on the tumor suppressor 
p53 resulting in its degradation. This indicates a dynamic and multifunctional role of 
the CSN because depending on its target protein it either induces its degradation or 
stabilizes it.   
 
The CSN inhibits the activation of NF-κB by stabilizing IκBα and this has a negative 
effect on apoptosis in epithelial cells271. In the activation and proliferation of mature T 
cells, NF-κB has been implicated in regulating survival signals at many stages of T- 
cell development and maturation273. Using a conditional knockout of Csn5 in 
thymocytes, Panattoni et al showed that there is a defective S phase progression and 
massive apoptosis of thymocytes. This was associated to a tremendous increase in 
p53 and its target genes and a downregulation of IκBα- and NF-κB-regulated pro-
survival genes274. Csn8-deficient peripheral T cells also exhibited a delayed 
progression from S phase to G2 and M phase275.  Of note, CSN has been shown to 
control the ubiquitinylation and deubiquitinylation of the ATP-binding cassette protein 
A1 (ABCA1)276. ABCA1 mediates the transfer of cellular free cholesterol and 
phospholipids to apolipoprotein A-I (apoA-I), an extracellular acceptor in plasma, to 
form high-density lipoprotein (HDL). ABCA1 synergizes with ABCG1 to mediate 
macrophage cholesterol efflux and protect against macrophage foam cell formation, 
infiltration of inflammatory cells, apoptosis and atherosclerosis277. Desensitization of 
ABCA1 towards the UPP which might result in effective cholesterol efflux represents 
a way of decreasing circulating monocytes and subsequent decrease in 
atherosclerosis.  
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The autophagy-lysosome pathway represents a second important route for the 
clearance of eukaryotic intracellular proteins. Autophagy regulates homeostasis in 
the cell in a nonselective or selective manner. During starvation, nonselective 
autophagy helps the cell to survive an energy crisis temporarily by self-eating portion 
of its cytoplasm. Selective autophagy serves as a quality control mechanism in the 
cell by removing aged/damaged organelles and aggregated proteins278. Again, the 
CSN has been shown to have a crucial role in autophagosome maturation through 
regulating the expression of Rab7. Impaired autophagosome maturation after 
ablation of Csn8 in a perinatal cardiomyocytes-restricted model drove 
cardiomyocytes into necrosis279. Taken together, the CSN seems to be a key player 
in regulation of cellular functions which are implicated in several diseases including 
perhaps cardiovascular disease.  
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1.7 Aim of the study 
Inflammatory processes play a crucial role in all stages of atherogenesis. As a key 
trigger, the activation of the NF-κB signaling pathway in endothelial cells and 
macrophages drives the expression of pro-inflammatory and pro-atherosclerotic 
genes. The COP9 signalosome (CSN), a multi-functional protein complex involved in 
the regulation of Cullin-RING-E3 ubiquitin ligases (CRLs), has emerged as a 
regulator of NF-κB signaling. This function has been assigned to the deneddylase 
activity of its subunit CSN5. The CSN has been suggested to exhibit an important 
pathophysiological role in cancerogenesis, but its contribution to inflammation has 
been less well studied. Although the CSN has been implicated in β2-integrin 
signaling, a process critical in inflammatory and atherogenic leukocyte recruitment, 
the role of the CSN in atherosclerosis has been unknown. Using test tube approach 
and animal models, the aims of the study were threefold: 
 
1. To probe the role of CSN5 in IKK/NF-κB signaling and atherogenic processes in 
the endothelium.    
2. To translate the in vitro findings to mouse atherosclerosis models by generating 
endothelial and macrophage-specific Csn5 knockout mice using the Cre/loxP 
recombination system.  
3. To follow CSN5 and CSN expression levels over the course of atherosclerosis 
pathogenesis in humans and mouse models.  
 
 
 
 
 
 
 
 
                                                                                                                                             
 
45 
2 MATERIALS 
2.1 Chemicals and reagents  
Substance Manufacturer 
DNA Ladder (1kb) Fermentas, St.Leon-Rot 
Acrylamide (30%) Biorad, München 
Ampicillin (100mg/ml) Sigma, München 
APS  Sigma, München 
DTT Sigma, München 
EDTA  Merck, Darmstadt 
Glycerol Sigma, München 
NuPAGE LDS sample buffer Invitrogen, Karlsruhe 
NuPAGE LDS running buffer Invitrogen, Karlsruhe 
NuPAGE LDS transfer buffer Invitrogen, Karlsruhe 
Penicillin/Streptomycin Invitrogen, Eggenstein 
Protease Inhibitor cocktail Roche, Manheim 
TEMED Biorad, München 
Methanol Roth, Karlsruhe 
Protein G Sepharose NEB, Frankfurt am Main 
Protein Marker – Multi MarkTM Invitrogen, Karlsruhe 
RPMI 1640 Invitrogen, Eggenstein 
Super Signal West Dura Pierce, USA 
Trypsin Invitrogen, Eggenstein 
Tween 20 Fluka, Switzerland 
β-Mercaptoethanol Sigma, München 
DMSO Sigma, München 
Endothelial Cell Growth Medium Promocell, Heidelberg   
Ethanol Carl Roth, Karlsruhe 
FCS Gibco, Eggenstein  
Ficoll-Paque plus GE Healthcare Europe GmbH, Freiburg 
Hank’s Balanced Salt Solution (HBSS) Biochrom. AG, Berlin  
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Substance Manufacturer 
Accutase PAA, Pasching 
Acetonitril Sigma, München 
Calcein-AM Calbiochem, USA  
Isopropanol KMF Laborchemie, Lohmar  
Calcium chloride Calbiochem, USA 
Potassium chloride Merck, Darmstadt  
Magnesium chloride Calbiochem, USA   
Sodium chloride Merck, Darmstadt  
Sodium dodecyl sulfate Merck, Darmstadt 
MG132 (proteasome inhibitor) Merck, Darmstadt  
Triton X-100 Sigma-Aldrich, Steinheim 
dNTP-Mix Fermentas, France 
Albumin Fraction V (BSA) Carl Roth, Karlsruhe 
Dulbecco’s PBS Sigma, München 
Dynabeads Protein A Invitrogen, Oslo 
Gentamycine Invitrogen, Karlsruhe  
Collagen G Biochrom. AG, Berlin     
TNF-α Peprotech, USA 
Trypan blue Invitrogen, Karlsruhe 
 
 
2.2 Enzymes and buffers for the enzymes 
Description Manufacturer  
Green GoTaq Flexi Buffer Promega, USA 
GoTaq polymerase Promega, USA 
Proteinase K Fermentas, St. Leon-Rot 
M-MLV Reverse Transcriptase Promega, USA 
M-MLV 5x Buffer Promega, USA 
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2.3 Primer pairs for qPCR 
Description Sequence                                                                   
CSN5 5’- CGCAAATTGCTTGAGCTGTTGTGGAA-3’      
 5’-CCAGCTGGGCTTCTGACTGC-3’  
 
CCL2 5’-GATCTCAGTGCAGAGGCTCG-3’ 
 5’- TGCTTGTCCAGGTGGTCCAT-3’  
 
VCAM1 5’-TGTGCCCACAGTAAGGCAGGC-3’ 
 5’- AGCTGGTAGACCCTCGCTGGA-3’ 
 
ICAM1 5’-GCTCCTGCCTGGGAACAACCG-3’ 
 5’-GGGGAGGGGTGCCAGTTCCA-3’ 
 
GAPDH 5’- GCCTCAAGATCATCAGC-3’ 
 5’-ACCACTGACACGTTGGC-3’ 
 
All primers above were manufactured by Sigma-Aldrich, Germany.  
 
 
 
2.4 Strains of bacteria and plasmids 
2.4.1 Strains of bacteria 
Strain Source 
XL-10 Invitrogen  
DH5α Invitrogen  
 
2.4.2 Plasmids 
Plasmid Resistance Source/Reference 
pGFP Kanamycin AG Bernhagen, RWTH 
pCDNA5/CTAP Ampicillin AG Lüscher, RWTH           
pCDNA5/CTAP-CSN5 Ampicillin AG Bernhagen, RWTH 
pIgκ3ConALuc Ampicillin AG Baens, K.U. Leuven               
pEQ176-βGal Kanamycin AG Bernhagen, RWTH                                                
Flag-CSN2 Ampicillin AG Schmid, M.U. Vienna                         
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2.5 Antibodies  
2.5.1 Primary antibodies  
Description Use Species Manufacturer  
Anti-CSN5 IP/WB/IHC rabbit Santa Cruz 
Anti-CSN3 IP/WB mouse Santa Cruz 
Anti-CSN1 IHC rabbit Enzo Life Science GmbH 
Anti-CSN8 IHC rabbit Enzo Life Science GmbH 
Anti-phosho-IKK1/2 WB rabbit Cell Signaling  
Anti-IκBα WB rabbit Cell Signaling 
Anti-IKK1 IP/WB rabbit Cell Signaling 
Anti-IKK2 IP/WB rabbit Cell Signaling 
Anti-Cullin1 WB rabbit Abcam 
Anti-β-actin WB mouse MP Biomedicals 
Anti-ICAM-1 FACS mouse Donation (AG Koenen) 
Anti-P-selectin-PE FACS mouse BD Bioscience 
Anti-CD31 IHC goat Santa Cruz 
Anti-IgG-PE FACS mouse BD Bioscience 
 
Detailed description of antibodies and their specific usage are noted in the methods and figure 
legends. 
 
2.5.2 Secondary antibodies  
Description Use Species Manufacturer  
Anti-rabbit HRP WB goat Pierce 
Anti-mouse HRP WB goat Amersham 
Anti-mouse-Cy3 FACS donkey Jackson ImmunoResearch             
Anti-rabbit-FITC IHC donkey Jackson ImmunoResearch                             
Anti-goat-Cy3 IHC donkey Jackson ImmunoResearch                        
 
 
 
 
 
 
 
                                                                                                                                             
 
49 
2.6 Media, buffers and solutions 
2.6.1 Media for cell culture 
Endothelial cell growth medium supplemented with FCS and supplement mix was 
purchased from Promocell, Heidelberg. RPMI medium was obtained from Gibco and 
was supplemented with 10% FCS and 1% penicillin-streptomycin.  
 
2.6.2 Media for culture of bacteria 
Description                                   Concentration  
Luria Bertani (LB) Medium             1% (w/v) NaCl 
                                                       1% (w/v) Bacto tryptone  
                                                       2% (w/v) Yeast extract 
                                                       1 mg/ml Ampicillin or Kanamycin * 
 
LB-Agar                                          1.5% (w/v) Bacto-Agar 
                                                       1 mg/ml Ampicillin or Kanamycin * 
                                                       Dissolved in LB Medium 
* This depends on the antibiotic resistance gene in the vector. 
 
2.6.3 Buffers and solutions 
Distilled water was added to all buffers unless otherwise stated. 
 
Description                                   Concentration 
FACS staining buffer*                    100 µl normal mouse serum (2% final) 
                                                      100 µl normal rabbit serum (2% final) 
                                                      100 µl normal human serum (2% final) 
                                                      333 µl 30% BSA (2% final) 
                                                      5 ml PBS  
 
HANKS Complete*                        500 ml Hank’s balanced salt solution (HBSS) 
                1 ml 30% BSA (0.06% final) 
                1.5 ml 100 mM EDTA (0.30 mM final) 
* For antibody stainings during flow cytometry experiments, these buffers were used in a ratio of 1:1. 
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Description                                   Concentration  
CoIP buffer                                    50 mM Tris-HCl 
                                                      100-150 mM NaCl 
                                                      15 mM EGTA 
                                                      0.1 % Triton X-100 
                                                      1 mM NaAzid 
                                                      10 % Glycerin 
                                                      0.5 mM Na3VO4 
                                                      1 mM DTT 
                                                      25 mM NaF 
                                                                 Protease inhibitor cocktail (1:100) 
 
1x LDS buffer                                 500 µL 4x NuPage LDS 
                                                       250 µL 1M DTT 
                                                       1250 µL distilled H2O 
 
Nuclear extract buffer 1 (NEB1)    10 mM Hepes                 
                                                                 10 mM KCl 
                                                                  0.1 mM EDTA 
                                                       5 mM Na4P2O7 
                                                       10 mM NaF 
                                                        Adjusted to pH 7.9 
 
Nuclear extract buffer 2 (NEB2)     20 mM Hepes                                                        
                                                       0.4 mM NaCl 
                                                       1 mM EDTA 
                                                       Adjusted to pH 7.9 
 
PBS                                               137 mM NaCl 
                                                      2.7 mM KCl 
                                                      1.5 mM KH2PO4 
                                                      8.1 mM Na2HPO4 
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Description                                 Concentration 
TBS (pH 7.2)                                20 mM Tris-HCl 
                                                    150 mM NaCl 
 
TE buffer (pH 8)                           10 mM Tris 
                                                    1 mM EDTA 
 
TBE                                              8.9 mM Tris-HCl 
                                                     8.9 mM Boric acid 
                                                     0.2 mM EDTA 
 
Ethidium bromide solution           10 mg/ml  
 
10x DNA gel loading buffer          0.2% Bromphenol Blue  
                                                     0.2% Xylene xylano  
                                                     0.2% Orange G 
                                                     60% Saccharose 
 
SDS PAGE Running buffer           5% 20x MES-running buffer                 
 
Transfer buffer                              0.5% 20x Transfer buffer  
                                                     25 ml Methanol   
 
Washing buffer                             0.05% Tween dissolved in TBS buffer                           
                                                                
Blocking buffer                             1-5% BSA or 5% non-fat dry milk  
 
Western blot strip buffer              50 mM Tris (pH 6.8)  
                                                    100 mM β-mercaptoethanol  
                                                     2% SDS 
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Description                                 Concentration 
Resolving gel                              12% (w/v) acrylamide/Bis 
                                                    375 mM Tris-HCl, pH 8.8 
                                                    0.1% (w/v) SDS 
                                                    0.1% (w/v) ammonium persulfate 
                                                    0.1% (v/v) TEMED 
 
Stacking gel                                5% (w/v) acrylamide/Bis 
                                                   125 mM Tris-HCl, pH 6.8 
                                                   0.1% (w/v) SDS (sodium-dodecylsulfate) 
                                                   0.1% (w/v) ammonium persulfate 
                                                   0.1% (v/v) TEMED 
                   
 
2.7 Multi-component systems   
Description Manufacturer  
Plasmid Maxi Kit Qiagen, Hilden  
RNeasy Mini Kit Qiagen, Hilden  
QIAshredder Qiagen, Hilden 
Express SybrGreenER qPCR Supermix Invitrogen, Karlsruhe  
HUVEC Nucleofector Kit Lonza, Cologne 
Bright-GloTM Luciferase Assay System Promega, USA 
β-Galactosidase Enzyme Assay System Promega, USA 
TransAM NF-κB Transcription factor ELISA Kit Active Motif, USA  
 
2.8 Equipment and consumables  
2.8.1 Equipment 
Equipment Manufacturer 
CO2 incubator Sanyo, München   
Electrophoresis Power Supply Pharmacia Biotech, Freiburg 
SDS-PAGE NuPAGE/ XCell SureLock Invitrogen, Karlsruhe  
Gel Electrophoresis-Apparatus Horizon 11.14 Invitrogen, Eggenstein 
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Equipment Manufacturer 
Beckmann J2-21 Centrifuge Beckmann, USA 
Microscope Olympus CK40 Olympus Co., Hamburg  
Heatblock Thermomixer Comfort Eppendorf, Hamburg 
LAS 3000 CCD Camera Fujifilm, Düsseldorf 
Centrifuge 5417 R Eppendorf  Eppendorf, Hamburg 
Dynal Magnetic Particle-Concentrator-S Invitrogen, Karlsruhe 
Nucleofector Device Lonza, Cologne 
Fluorescence Microscope IX50 Olympus, Hamburg  
Fluorescence Microscope Leica DMLB Leica Microsystems, Wetzlar 
FACSCantoTM II Flow Cytometer BD Bioscience, Heidelberg 
Micro Centrifuge Carl Roth, Karlsruhe 
Sonifier Cell Disruptor B15 Branson, USA 
VICTOR2 1420 Multilabel Counter PerkinElmer, USA 
Flow Adhesion Chamber IMCAR, RWTH Aachen 
Thermal Cycler 7900HT Applied Biosystems, Darmstadt 
T3000 Thermocycler Biometra, Göttingen  
PCR-machine Primus 96 MWG AG Biotech, Ebersberg 
Neubauer Cell Chamber Paul Marienfeld, Lauda-Königshofen  
PHM82 Standard pH-Meter Radiometer, Denmark 
AF 100 Flake ice maschine Scotsman, Italy  
High temperature dry block heater Grant Instruments, UK 
MS2 Mini shaker IKA, Staufen 
Shaker Rocky CTF, Wasserburg 
Spectrophotometer Nanodrop ND-1.000 PeqLab Biotech. GmbH, Erlangen 
Water bath Typ 1004 GFL, Burgwedel 
Centrifuge EBA12 Hettich, Tuttlingen 
Centrifuge Z383K Hermle, Wehingen 
Centrifuge Z400K Hermle, Wehingen 
Tissue culture hood KOJAIR Tech Oy, Finnland  
-152°C cryogenic freezer Sanyo Electric Biomedical, Japan 
-80°C ultra low freezer Sanyo Electric Biomedical, Japan 
-20°C freezer Bosch, Stuttgart  
4°C refrigerator Liebherr, Ochsenhausen  
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2.8.2 Consumables  
Description Manufacturer 
Cell scraper Nunc, USA 
ELISA-Microplate (96 wells) white Nunc, USA 
FACS tube (5 ml) Falcon, Heidelberg 
Filter 0.2 µm  Whatmann GmbH, Dassel  
Gel blotting paper  Schleicher & Schuell Bioscience, Dassel 
Needle (25 G, 23 G)  BD Microlance, Heidelberg 
Cryogenic vials  Nalgene, USA 
NuPage/ Bis-Tris 4-12 % Gel  Invitrogen, Karlsruhe  
NuPage gel cassette   Invitrogen, Karlsruhe  
Glass slide          Langenbrinck, Emmendingen 
Glass slide folder Carl Roth, Karlsruhe 
Petri dish Greiner Bio-One GmbH, Frickenhausen 
Pipette tips blue (1000 µl)  Brand, Wertheim  
Pipette tips yellow (200 µl)  Brand, Wertheim  
Pipette tips white (20 µl)   Sarstedt, Nümbrecht  
Nitrocellulose transfer membrane Whatman GmbH, Dassel  
Syringe BD Microlance, Heidelberg 
Centrifuge tube Greiner Bio-One GmbH, Frickenhausen 
 
2.9 Cell lines used 
Description Origin/Phenotype Source 
HUVECs Human Umbilical Vein Endothelial Cells PromoCell, Heidelberg  
THP-1 Human Acute Monocytic Leukemia Cells IMCAR, RWTH Aachen  
 
2.10 Mice  
Description Source 
LysMCre-Csn5-KO mice AG Gessner, Universitätsklinikum Erlangen 
Apoe-/- mice AG Schober, RWTH Aachen 
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3 METHODS 
3.1 Cell culture, cell counting, transfection, and gene silencing 
Culturing of mammalian cells was done under sterile conditions in a laminar flow 
hood and maintained in a CO2 incubator at 37°C and a humidified 5% CO2 
atmosphere. Human Umbilical Vein Endothelial Cells (HUVECs) were purchased 
from PromoCell, plated on cell culture dishes coated with collagen and cultured in 
endothelial cell growth medium, according to the manufacturer’s recommendations. 
These primary cells were used at passages ranging from 3 to 5 for all experiments. 
Cells were counted using the Neubauer counting chamber under a light microscope. 
The number of cells per milliliter of medium was calculated using the formula: 
number of cells/ml = n/4*104. Transfection of HUVECs with small interfering RNA 
(siRNA) or with plasmid DNA was performed by electroporation using the HUVEC 
Nucleofector Kit following the manufacturer’s instructions. The concentration of 
siRNA duplexes was maintained at 3 µg/ml throughout the experiment whereas that 
of plasmid DNA varied depending on the experiment. In the overexpression 
experiments, GFP was cotransfected to follow the transfection efficiency. After 
electroporation, cells were allowed to recuperate for 48 h (in overexpression 
experiments) or 96 h (in gene silencing experiments) before being used in 
experiment. Where indicated, HUVECs were stimulated with 20 ng/ml human TNF-α 
for the indicated time periods. For coimmunoprecipitation, HUVECs were pretreated 
for 1 h with 50 µmol/L MG132 to block the activity of the proteasome, prior to TNF-α 
treatment. The open reading frame of CSN5 was cloned into the 
pCDNA5/FRT/TO/CTAP vector by means of molecular cloning techniques to create 
the CTAP-CSN5 construct.  The following predesigned siRNAs (MWG Biotech AG) 
were used for gene knockdown experiments: CSN5: 5’- 
GCUCAGAGUAUCGAUGAAAdTdT-3’280;CSN2: 5’-GCACUGAAACAAAUGAUUATT-
3’242; scrambled: 5’-AACAGUCGCGUUUGCGACUTT-3’.  
 
3.2 Freezing and thawing of mammalian cells 
Frozen stocks of cell lines were stored in 1 ml cryovials in cryogenic freezer. Cells 
were first harvested and then resuspended at a concentration of 106 cells/ml 
complete medium containing 5% (v/v) dimethylsulfoxide (DMSO).  
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The cryovials were placed overnight at -80°C in a cryocontainer to ensure slow 
cooling and then transferred to -152°C cryogenic freezer for long-term storage. For 
thawing of cells, cryovials were rapidly thawed in a 37°C water bath. Cells were 
slowly added to 4 ml warm growth medium, centrifuged and resuspended in growth 
medium. 
 
3.3 Cell lysis, coimmunoprecipitation, western blot and immunodetection  
3.3.1 Cell lysis 
For total cell lysates, HUVECs were washed with cold PBS and lysed with 1x 
NuPAGE-LDS-sample buffer containing 1 mmol/L DTT. Cells were further treated 
with sonifier cell disruptor to ensure complete lysis. For coimmunoprecipitation, the 
cells were lysed in coimmunoprecipitation (CoIP) buffer (50 mmol/L Tris-HCl, 150 
mmol/L NaCl, 15 mmol/L EGTA, 1% Triton X-100, 1 mmol/L DTT, 25 mmol/L NaF, 
1% Proteinase Inhibitor Cocktail). 
 
3.3.2 Coimmunoprecipitation  
Cell lysates were made by homogenization. After centrifugation for 5 min at 14000 
rpm, the supernatant was transferred to new Eppendorf tubes. The supernatants 
were incubated overnight with 2 µg/ml specific antibodies or an isotype control, 
followed by incubation with dynabeads protein A for 2 h. The Eppendorf tubes were 
centrifuged for 2 min at 4°C at 5000 rpm. The supernatants were discarded and the 
beads washed three times with 500 µl CoIP buffer. Immunoprecipitated proteins were 
eluted with 1x NuPAGE-LDS-sample buffer at 70°C for 10 min. Immunoprecipitated 
proteins were directly separated by SDS-PAGE or stored at -20°C for later use. 
 
3.3.3 Western blot and immunodetection 
Total cell lysates or immunoprecipitated proteins were directly separated by SDS-
PAGE at 190V in NuPAGE/XCell SureLock-chamber with NuPAGE MES-running 
buffer. Protein samples were first concentrated in a stacking gel before migrating into 
the resolving gel. Proteins separated by SDS-PAGE were transferred to a 
nitrocellulose membrane XCell II Blot module from Invitrogen. The blot was run at 33 
V for 1.5 h under cold conditions after which it was incubated in BSA at RT for 1 h to 
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prevent non-specific binding. After blocking, primary antibodies were incubated either 
at room temperature for 1 h or at 4°C overnight depending on the affinity of the 
antibody for the antigen being pursued. The concentration of BSA used for these 
incubations varied from 1% to 3% BSA depending on the specificity of the antibody 
used. In all experiments, secondary antibodies were incubated at room temperature 
for 1 h in 1% BSA. Primary anti-CSN5 (FL-337) and anti-CSN3 (RR12) antibodies 
were purchased from Santa Cruz Biotechnology. Anti-phosho-IKK1/2 (Ser 176/180, 
#2687), anti-IκBα (#9242), anti-IKK1 (#2682) and anti-IKK2 (#2678) antibodies were 
bought from Cell Signaling Technology. Anti-Cullin1 (ab2964) and anti-β-actin 
(#08691001) antibodies were purchased from Abcam and MP Biomedicals, 
respectively. As secondary antibodies, HRP-conjugated anti-mouse or anti-rabbit 
antibodies (Pierce) were used and blots were developed with Super Signal West 
Dura Extended Duration ECL reagent (Pierce/KMF). Protein bands were visualized 
with a LAS 3000 Imager and quantified using the Aida Image Analyzer Software 
(Fuji/Raytest). 
 
3.4 Cellular fractionation: preparation of nuclear and cytoplasmic extract   
To separate the nuclear fraction from the cytoplasmic fraction, HUVECs, pretreated 
depending on the experiment, were lysed in nuclear extract buffer 1 (NEB1) 
containing freshly added 1 mM Na3VO4. Cells were transferred into eppendorf tubes 
and incubated on ice for 15 min. 0.5% NP-40 was added and the tubes were 
vortexed for 10 sec followed by centrifugation at 13000 rpm for 30 sec at 4°C. The 
supernatant was collected as the cytoplasmic fraction and the pellet resuspended in 
nuclear extract buffer 2 (NEB 2) and incubated on ice for 30 min with vortexing in 
between the incubation period. The tubes were centrifuged at 13000 rpm for 5 min at 
4°C after which the supernatant was collected as the nuclear extract.  
 
3.5 NF-κB DNA binding activity  
The binding of NF-κB to DNA was monitored using the TransAM NF-κB Transcription 
factor ELISA Kit from Active Motif, USA. TransAM NF-κB family kit designed 
specifically for the study of NF-κB pathways, contain a 96-well plate to which 
oligonucleotides containing NF-κB consensus binding site have been immobilized.  
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The activated NF-κB contained in nuclear extracts specifically binds to this 
oligonucleotide. Nuclear extracts were prepared as indicated in 3.4 and incubated in 
the 96-well plate to which oligonucleotides containing NF-κB consensus binding site 
have been immobilized. An antibody directed against p65 was used to detect the NF-
κB complex bound to the oligonucleotide. A secondary antibody conjugated to HRP 
was incubated to aid a sensitive colorimetric readout that was quantified by VICTOR2 
1420 multilabel counter spectrophotometer from PerkinElmer, USA.  
 
3.6 NF-κB luciferase reporter assay  
Reporter gene assay relies on protein translation and measures the regulatory 
potential of DNA-sequence. This can be achieved by linking a promoter sequence to 
an easily detectable reporter gene such as that encoding for the firefly luciferase.  
This was done for NF-κB to monitor its regulation in pretreated HUVECs. The NF-κB 
luciferase reporter construct pIgκ3ConALuc (1 µg) and the β-galactosidase 
expression construct pEQ176 (1 µg) were cotransfected with either siRNA duplexes 
or plasmid DNA, depending on the experiment, into HUVECs. After 48 h 
(overexpression experiments) or 96 h (gene silencing experiments), cells were 
harvested using reporter lysis buffer and assayed for luciferase and β-galactosidase 
activities using Bright-Glo TM Luciferase Assay System and β-Galactosidase Enzyme 
Assay System according to manufacturer’s protocol. The colorimetric readout was 
quantified by a plate reader. Luciferase values were normalized for β-galactosidase 
values to correct for differences in transfection efficiency (plotted as luciferase 
activity/β-galactosidase activity).  
 
3.7 Quantitative real-time PCR (RT-PCR) 
The real time-PCR technique is based on the ability of the fluorescent dye SYBR 
Green to bind to double-stranded DNA; the increase in double-stranded DNA can 
therefore be directly detected. Thus, the increase of fluorescence over the reaction 
time can be linked to the mRNA or total RNA concentration used in the experiment. 
Based on this knowledge, RNA was isolated from HUVECs using the RNeasy Mini 
Kit and the amount determined using Spectrophotometer Nanodrop ND-1.000. A 
maximum of 1 µg RNA was reverse-transcribed using oligo-dT primers.  
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RT-PCR analysis was performed using Express SybrGreenER qPCR Supermix in a 
thermal cycler 7900HT with specific human primer pairs for CSN5, CCL2, VCAM-1, 
ICAM-1 and GAPDH as reference gene.  
 
cDNA synthesized as follows:          1 µg template RNA 
                                                          2 µl 10 µM oligo-dT primer 
                                                          H2O to a final volume of 17.5 µl 
                                                          Incubation at 70°C for 5 min  
                                                          5 µl 5x M-MLV reverse transcription buffer    
                                                         1.5 µl dNTP mix (10 mM each)  
                                                          Incubation at 37°C for 5 min  
                                                         1 µl M-MLV reverse transcriptase                                                                     
                                                         Incubation at 42°C for 60 min 
 
RT-PCR mix was performed as:     12.5 µl 2x Express SybrGreenER qPCR Supermix  
                                                        forward primer to a final concentration of 0.2 µM 
                                                        reverse primer to a final concentration of 0.2 µM 
                                                        2 µl cDNA or H2O 
                                                        H2O to a final volume of 25 µl 
 
RT- PCR Program:                        
Initial activation 95°C, 20 sec 
Denaturation 95°C, 3 sec  
Annealing 60°C, 30 sec                                             
Melting curve 60°C to 95°C; read every 0.5°C, hold 1 sec between reads                                                                   
 
The relative mRNA expression was estimated as: 
                                                                                 ∆Ct = Ct (target) - Ct (reference) 
                                                                                ∆∆Ct = ∆Ct - ∆Ct (target control) 
                                                                                 relative mRNA expression: 2 (-∆∆Ct) 
Ct: Cycle number at which the fluorescence intensity exceeds a determined 
threshold. 
 
40 x 
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3.8 Flow cytometry 
Flow cytometry is used to analyze cells by their size, granularity and surface 
expression of proteins using fluorescently labeled detection antibodies or to sort cell 
populations (FACS =Fluorescent activated cell sorting). In a buffer stream, one cell at 
a time passes by an argon laser, which excites fluorescently labeled cells. 
Measurements of the size (forward scatter) and granularity (sideward scatter) are 
independent of the fluorescence signal. Measurement of fluorescence intensity using 
fluorescently labeled antibodies was done to examine the expression of chemokines 
and adhesion molecules on the surface of HUVECs. To do this, pretreated HUVECs 
were washed with Hank’s Balanced Salt Solution (HBSS) containing 0.3 mmol/L 
EDTA and 0.1% BSA. Cells were labeled with specific antibodies: a primary anti-
ICAM1 antibody and a secondary Cy3-conjugated antibody; anti-P-selectin-PE 
antibody or the appropriate isotype controls. After careful washing, cell suspensions 
were measured on a FACSCanto TM II (BD Bioscience) and analyzed using FlowJo 
software (Tree Star). The results were displayed as histograms showing the 
logarithmic distribution of the fluorescence intensity or as diagrams demonstrating 
the change in mean fluorescence intensity (MFI).  
 
3.9 Laminar flow adhesion assay  
A key step in atherogenesis is the expression of adhesion molecules and secretion of 
chemokines upon activation of endothelial cells which trigger the binding and arrest 
of monocytes on the activated endothelium. This can be pursued in an in vitro setting 
which mimics the in vivo situation as depicted in Figure 14. 
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Figure 16 Setup of flow adhesion assay. Monocytes prestained with calcein were perfused over 
HUVECs monolayer for 4 min. Monocytes adhered depending on expressed adhesion molecules on 
the surface of HUVECs were counted. 
 
Adhesion of calcein-AM (Molecular Probes)-labeled THP1 cells on confluent HUVEC 
monolayers, pretreated with 20 ng/mL human TNF-α as indicated, was quantified in 
parallel wall chambers under flow conditions (1.5 dynes/cm2, 4 min)9.  
 
3.10 Immunohistochemistry and immunofluorescence on human lesions 
Collection of histologically normal human carotid artery specimens from autopsied 
individuals and early and advanced human carotid artery lesions from patients 
undergoing endarterectomy was approved by an institutional review committee and 
with the patients’ informed consent, in accordance with institutional guidelines 
(EK287/11). For immunohistochemistry, an antibody against CSN5 (FL-337, Santa 
Cruz Biotechnology) or an appropriate isotype control antibody was used and 
visualized by the immunohistochemical avidin-biotin complex method with alkaline 
phosphatase enzyme development (Vector Laboratories, Ontario, Canada). Cells 
were counterstained by Mayer’s hemalaun. Double immunofluorescence staining 
was performed with antibodies against CSN5 (FL-337, Santa Cruz Biotechnology), 
CSN1 (PW8285, Enzo Life Science GmbH) and CSN8 (PW8290, Enzo Life Science 
GmbH) in combination with anti-CD31 (M-20 sc-1506, Santa Cruz Biotechnology), 
and proteins were visualized with FITC- (for CSN) or Cy3-conjugated (for CD31) 
secondary antibodies (Jackson ImmunoResearch). Nuclei were counterstained by 4′, 
e.g. HAoECs
 
HUVECs 
Adhered monocytes on EC surface 
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6-diamidino-2-phenylindole (DAPI). Images were recorded with a Leica DMLB 
fluorescence microscope and charge-coupled device camera, and image analysis 
was performed with Diskus Software (Hilgers). 
 
3.11 Animal experiments  
3.11.1 Generation of macrophage-specific Csn5 KO mice  
LysMCre-Csn5-KO mice (provided by AG Gessner, Universitätsklinikum Erlangen) 
were obtained by crossing male mice with loxP-flanked Csn5 with female mice 
expressing Cre under control of the lysozyme M gene (The Jackson Laboratory). 
Heterozygous mice were then bred to obtain homozygous KO mice which were 
further crossed with Apoe−/− provided by AG Schober, IMCAR RWTH Aachen) to 
obtain macrophage-specific deletion of Csn5 on Apoe−/− background. Heterozygous 
and wild-type littermates were used for experiments. Genomic DNA was amplified 
with specific primers as below.  
 
PCR distinguishes wild-type, heterozygous and homozygous mice as described by 
AG Gessner.  
 
Primers: Cre 8:  5‘-CCC AGA AAT GCC AGA TTA CG-3‘ 
 
  Mlys1: 5‘-CTT GGG CTG CCA GAA TTT CTC-3‘ 
 
  Mlys2: 5‘-TTA CAG TCG GCC AGG CTG AC-3‘ 
 
WT band is 350 bp, LysMcre: 700 bp and 1.7 kb (see below) 
----------------------------------------------------------------------------------- 
Program:   94 °C 5 min 
   94 °C 30 sec 
   58 °C  30 sec    35 x 
   72 °C 50 sec 
   72°C 5 min 
 
(1.7 kb band for the LysMcre allele was never obtained) 
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PCR genotyping for Csn5-loxP mice 
 
PCR distinguishes wt, heterozygous and homozygous mice 
 
Primers: InII1for: 5’-GGT CAG AAA GCT AGG CCT AAG AAG G-3’ 
 
  ExII1rev: 5’-GGC ATG CAT CAC CAT TTT CAG TAG-3’ 
 
Bands: WT/WT - 397 bp; WT/Flox - 397 bp and 484 bp; Flox/Flox - 484 bp.  
Program: 1. 94 °C 60 s    
  2.  94 °C 30 s 
  3.  55 °C 30 s     40 x 
  4.  72 °C 40 s 
  5.  72 °C 5 min 
 
3.11.2 Genotyping of Mice  
Efficient pursuit of animal research and reduction in the number of animals involved 
in a research project is achieved through proper identification of genetically 
engineered animals. DNA extracted from tissues of young rodents is mostly used in 
determining the genotype of these animals. DNA for PCR analysis can be obtained 
from ear punches, hair or fecal samples, oral or rectal swabs. Depending on the 
requirements of the study, investigators are urged to consider these noninvasive 
alternatives. Larger amounts of DNA are required for Southern Blot determination of 
the genotype. Obtaining tissue from a mouse for DNA analysis via tail biopsy is a 
safe, effective and humane procedure that causes minimal or transient pain and 
distress when performed properly. DNA prepared from tail biopsies is suitable for 
analysis by either Southern Blot or PCR.  To check the genotype of mice used in this 
study, a tail biopsy was carried out in order to get enough DNA for PCR analysis 
while at the same time minimizing the stress on the mice. After taking biopsies from 
the tail, 500 µl tail buffer (100 mM Tris HCl (pH 8.5), 5 mM EDTA, 200 mM NaCl, 
ATG
NLScre
FRT 2              3         4
ATG
2              3         4 
MLys1 MLys2 
350 Bp
MLys1 MLys2 Cre8
700 Bp
1700 Bp
Wild type-allele 
LysMcre-allele
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0.2% SDS) containing 10 µl Proteinase K was added to each tail in 1.5 ml eppendorf 
tubes. The tails were either incubated in 56°C water bath overnight or in a 
thermomixer at 56°C for 2-3 h with vigorous shaking and vortexing. The tubes were 
centrifuge at 14000 rpm for 5 min at RT, after which the supernatant was transferred 
into new tubes. 500 µl isopropanol was added to the supernatant and shook until 
white fibers were visible indicating DNA precipitation. The tubes were again 
centrifuged at 14000 rpm for 5 min at 4°C and the supernatant discarded. 500µl of 
70% ethanol was added to the resulting pellet followed by centrifugation at 14000 
rpm for 5 min at 4°C. The supernatant which is primarily ethanol was removed and 
the pellet dried at 37°C on a thermomixer. The dried pellet which is basically DNA 
was dissolved in 200µl distilled water and vortexed several times to ensure complete 
solvation. The concentration and purity of the resulting DNA was measured with 
Nanodrop ND-1000 Spectrophotometer and used directly for PCR analysis or stored 
at -20°C.  
 
3.11.3 Isolation of bone marrow cells and generation of bone marrow-derived 
macrophages  
Mice were sacrificed by cervical dislocation and the abdomen and hind legs were 
sterilized with 70% ethanol. An incision in the midline of the abdomen was made and 
was clipped outward to expose the hind legs. The femur was separated from the tibia 
by cutting the knee joints followed by removal of muscle tissue from the bones. The 
bones were then cut at both ends and flushed with RPMI medium containing 1% 
penicillin-streptomycin and 10% FCS using 5 ml syringe and 25-gauge needle. 
Single-cell suspensions were made by pipetting the bone marrow cells up and down. 
The cells were passed through 40 µM cell strainer and the strainer washed with 
another 5 ml medium. Cells were incubated with erythrocytes lysis buffer for 3 min 
and the reaction stopped with RPMI medium followed by additional washing with 
RPMI medium. Centrifugations were done at 1250 rpm (option: slow) for 10 min. 
Single-cells were counted and incubated in medium containing 25 ng/ml M-CSF for 
differentiation. Cells were washed with PBS every 2-3 days and incubated in fresh M-
CSF containing medium. Progenitors of macrophages adhered to the cell dish and 
were not washed away. Macrophages were fully differentiated at day 6-7 and were 
used for experiments.  
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3.11.4 Mouse model of atherosclerotic disease progression 
LysMCre-Csn5-KO and their wild-type littermates, all on Apoe−/− background, were 
fed an atherogenic diet containing 21% fat (Altromin) for 12 weeks. Thereafter, the 
mice were anesthetized with 10% ketamine mixed with 2% xylazine and isotonic 
NaCl solution intraperitoneally. Cardiac puncture was performed with 10% Na+-citrate 
to draw blood and the thorax was opened to facilitate drawing of any remaining 
blood. Part of the blood was stored in EDTA tubes for FACS analysis and the 
remaining stored in serum tubes. Supernatants from the blood in serum tubes were 
collected after centrifugation at 3000 rpm for 15 min and flash-frozen in liquid 
nitrogen and stored at -80°C for further analysis like secretion of cytokines. The heart 
and its vasculature were rinsed with PBS until the liver was uncolored. Lymph nodes, 
spleen, femur and tibia were harvested, flash-frozen and stored at -80°C for further 
use. After harvesting these organs, the heart and its vasculature were again rinsed 
with 4% PFA solution containing sucrose and EDTA. The heart, aortic arch and the 
descending aorta were harvested by in situ perfusion fixation with 4% PFA. The heart 
was sectioned with a microtome to get access to the aortic root.   
 
The extent of atherosclerosis was assessed in aortic roots and in the descending 
aorta by either staining of 5 µm transversal sections, 5 sections per mouse, or the 
prepared aorta respectively for lipid deposition with Oil-red-O. After staining with Oil-
red-O, tissue sections were counterstained with hemalaun and then washed with 
PBS until the buffer remained clear. Images were recorded with a Leica DMLB 
fluorescence microscope with CCD camera and quantification done by computerized 
image analysis (Diskus software, Hilgers, Aachen, Germany). All animal experiments 
were conducted according to the protocol approved by local authorities and complied 
with German animal protection law.  
 
3.12 Bacteria culture and transformation  
3.12.1 Bacteria culture 
Strains of Bacteria were plated on agar selection plates and incubated overnight at 
37°C. Colonies on the plate were then selected and inoculated in LB medium 
containing the antibiotic of interest.  
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The inoculum was then incubated overnight at 37°C with agitation. After 
centrifugation, the pellets were used for the purpose of the experiment or stored at -
20°C for further used.  
 
3.12.2 Transformation of bacteria  
Competent cells were thawed on ice for about 15 min. The plasmid DNA was mixed 
with the competent cells in a tube and incubated on ice for 30 min. The tube was 
transferred to a 42°C water bath for 90 sec (heat shock). This sudden change in 
temperature caused the pores to open up to larger sizes, allowing DNA molecules to 
enter. The tube was then quickly transferred on ice for 2 min causing the pores to 
close up again trapping the DNA inside. 1 ml of LB medium was added to the cells 
and incubated at 37°C for 1h with agitation. After centrifugation at 4000 rpm for 5 
min, the pellets were resuspended in about 100 µl LB medium and plated on agar 
selection plate containing preferred antibiotic. The plates were incubated overnight at 
37°C.  
3.13 Plasmid preparation 
The isolation of plasmid DNA from competent cells was achieved through Maxi- or 
Mini- preparations using QIAprep Spin Miniprep Kit and Plasmid Maxi Kit from 
QIAGEN. For Minipreps, the manufacturer’s protocol was closely followed to obtain 
purified DNA. For Maxipreps, 200 – 300 ml inoculum incubated overnight at 37°C 
with agitation was centrifuged at 6000 rpm for 15 min using the Beckmann J2-21 
Centrifuge. Resulting pellet was weighed and resuspended in buffer P1; for every 2 g 
pellet, 10 ml of buffer P1 was added. Equal volume of buffer P2 was added to the 
suspension and incubated for 5 min at room temperature. Pre-chilled buffer P3 was 
also added at the same volume as buffer P1 followed by incubation on ice for 20 min. 
The suspension was centrifuged at 17000 rpm for 30 min using the Beckmann J2-21 
Centrifuge. The supernatant was run through a column equilibrated with 10 ml 
equilibration buffer and the bound DNA was washed three times with washing buffer.  
The washed DNA was eluted with 15 ml elution buffer followed by addition of 10.5 ml 
isopropanol. The eluted DNA was pelleted by centrifugation at 17000 rpm for 30 min 
and the pellet was subsequently dissolved in TE buffer followed by the addition of 
pre-chilled absolute ethanol and stored at -80 °C for 30 min.  
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The DNA was again pelleted by centrifugation at 13200 rpm for 30 min and then 
dissolved in TE buffer. The concentration and purity of DNA was determined and 
stored at -20 °C for further use. 
 
3.14 Measurement of DNA concentration  
The concentration and purity of DNA was determined using the Nanodrop ND-1000 
Spectrophotometer. The purity was determined from the ratio of the absorption at 
260 and 280 nm which the spectrophotometer measures and generates by itself.  
 
3.15 Digestion of DNA with restriction enzymes  
DNA digestion was carried out with 3-4 U endonucleases per µg of DNA and 10% 
(v/v) reaction buffer. The reaction was incubated at 37°C for 2 h. 
  
3.16 Polymerase chain reaction (PCR)  
The amplification of DNA using polymerase chain reaction was carried out in PCR 
Primus 96 Plus Thermocycler. Listed below are the components of the PCR, their 
respective concentrations and the programme used.   
 
Components Concentration                  PCR - programme 
DNA template  
Primer- forward  
Primer- reverse 
Taq polymerase buffer 
MgCl2 
dNTP 
ddH20 
Taq polymerase  
1 µg 
10 pM 
10 pM 
10x 
25 mM 
10 mM 
18.5 µl 
3 U 
Step                    T (°C)     t (min) 
Initialization            95             2                
Denaturation          95              1  
Annealing               58- 63       1           35x     
Elongation              72              3 
Final Elongation      72             5 
Final hold                 8              ∞ 
                  
 
                                                                                                                                             
 
68 
3.17 Separation of DNA fragments on agarose gel 
The fragments of DNA were separated on 1% agarose gel with 1x TBE buffer using 
the Horizon® 11.14 gel electrophoresis apparatus from Biometra. 10x DNA loading 
buffer was added to the DNA sample in a ratio of 1:5 loading buffer to DNA volume. 
DNA samples were then loaded on the gel and ran at 120V for 35-40 min. After 
running, the DNA band was visualized with UV light after incubation in ethidium 
bromide for 10-15 min.  
 
3.18 Statistical analysis  
Numerical data represent mean for 2-6 independent experiments depending on 
experiment as in figure legends, with range/2 (for n =2) and SEM (for n=3)  and were 
analyzed by two-tailed t-test with or without Welch’s correction, one- or two-way 
ANOVA with Newman-Keuls or Bonferroni post test, as appropriate (Graphpad Prism 
5.0 software). 8-10 mice per group were used for in vivo atherosclerosis studies. 
Observed differences with p<0.05 were considered to be statistically significant. 
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4 RESULTS 
4.1 CSN5 controls the deneddylation of cullins in endothelial cells  
To begin to investigate whether CSN5, the only subunit of the CSN with known 
catalytic activity, has a functional role in the atherogenic endothelium, CSN5 
expression was transiently silenced in HUVECs using siRNA technology (Figure 17a-
b). The effect on CUL1 neddylation was also examined. As shown in Figure 17a and 
c, reduction of CSN5 protein led to enhanced CUL1 neddylation, as evidenced by an 
increase in the density of the slower migrating CUL1 band in SDS-PAGE gels which 
was confirmed by anti-nedd8 antibody. Knock-down of CSN2 also promoted CUL1 
neddylation, although to a smaller degree, and also led to a decrease in CSN5 
protein levels (Figure 17a-b), confirming previous reports that suppressing CSN2 
destabilizes the CSN complex and reduces the levels of other CSN subunits237, 242 as 
well as the deneddylation activity of the CSN complex. Thus, these data indicate that 
in HUVECs, CSN5 and CSN2, and hence the CSN complex, are actively involved in 
the deneddylation of cullins. 
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Figure 17 CSN5 triggers the deneddylation of CUL1 in HUVECs. HUVECs were transiently 
transfected with CSN5 siRNA or scrambled control siRNA (control). 96 h post transfection, cells were 
harvested for Western blot analysis. Different lanes of the same blot (same gel and exposure) were 
combined as indicated by the dotted lines, after excluding irrelevant samples. (a) Immunodetection of 
CSN5, CUL1, Nedd8 and β-actin using corresponding specific antibodies. Shown is a representative 
immunoblot. (b, c) Densitometric quantification of CSN5 (b) and CUL1-Nedd8 (c) in immunoblots as in 
(a), after normalization to β-actin. The graph represents means of 2-3 independent experiments, with 
the range/2 (for n=2) or SEM (for n=3). One-way ANOVA with Newman-Keuls post-test was applied 
for comparison versus control:  **p<0.01.  
 
4.2 CSN inhibits the NF-κB pathway in TNF-α-stimulated endothelial cells 
Contrasting findings have been observed for the effect of the CSN complex on IκB-α 
stability in different cell types. Whereas the CSN has been shown to destabilize basal 
IκB-α in a cervical adenocarcinoma cell line242, CSN5 knock-down markedly reduced 
steady-state IκB-α levels in thymocytes274. This study specifically focused on the role 
of CSN5 in HUVECs and demonstrated a significant decrease in basal IκB-α levels 
upon CSN5 knock-down (Figure 18a). Similarly, silencing of CSN2 reduced IκB-α 
protein amount (Figure 18f). Furthermore, the inducible degradation of IκB-α upon 
TNF-α challenge, i.e. mimicking inflammatory or atherogenic stimulation, was 
significantly enhanced by CSN5 reduction (Figure 18b-c). This coincided with a 
markedly increased activation of NF-κB as read out by NF-κB binding to DNA activity 
(Figure 18d) and a luciferase reporter gene assay (Figure 18e). Inversely, transient 
overexpression of CSN5 using a CTAP-CSN5 fusion construct increased steady-
state IκB-α levels (Figure 19a-b) and also delayed IκB-α degradation upon TNF-α 
stimulation (Figure 19c). In line with this, NF-κB activity was significantly reduced in 
both unstimulated and TNF-α-stimulated HUVECs (Figure 19d). Thus, these data 
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clearly show that CSN5 impairs basal and TNFα-triggered activation of NF-κB by 
stabilization of the NF-κB inhibitor IκB-α. 
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Figure 18 CSN modulates the NF-κB pathway in TNF-α-stimulated endothelial cells. HUVECs were 
transiently transfected with siRNA that targets CSN2, CSN5 or scrambled control RNA. After 96 h, 
cells were either left untreated or stimulated with TNF-α for the indicated time periods as indicated, 
and prepared for Western blot analysis. The CSN5 knockdown rate was similar to that in Figure 1. (a) 
Quantification of basal IκB-α normalized to β-actin; these data represent means±SEM of 4 
independent experiments. Two-tailed t-test: *p<0.05. (b) Immunodetection of IκB-α, CSN5, and β-actin 
in cell lysates of HUVECs treated with TNF-α for the indicated time points. Different lanes of the same 
blot (same gel and exposure) were combined as indicated by the dotted lines, after excluding 
irrelevant samples (c) Quantification of IκB-α, normalized to β-actin. The data represent means±SEM 
of 3 independent experiments. (d) Binding of NF-κB to NF-κB consensus sequence immobilized on a 
plate. (e) NF-κB-dependent luciferase activity after normalization to β-galactosidase activity, relative to 
the untreated control. Data represent means±SEM of one representative experiment out of 4, 
performed in triplicate each. (c,e) Two-way ANOVA with Bonferoni post-test for comparison of control 
versus CSN5 siRNA: *p<0.05, **p<0.01, ***p<0.001. One-way ANOVA with Newman-Keuls post-test 
for comparison versus unstimulated cells: #p<0.05, ###p<0.001. (f) Left panel: Representative 
immunodetection of IκBα and β-actin, after silencing the gene expression for CSN2, using the 
corresponding specific antibodies. Right panel: Quantification of IκBα, normalized to β-actin. The 
graph represents means±SEM of 4 independent experiments. Two-tailed t-test: **p<0.01. 
 
 
f 
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Figure 19 CSN5 stabilizes ΙκB-α and impairs TNFα-induced NF-κB activation in ECs. HUVECs were 
transiently transfected with a CTAP-CSN5 fusion construct or empty vector as control. After 48 h, cells 
were either left untreated or stimulated with TNF-α for the indicated time periods. (a) Immunodetection 
of basal IκB-α, CSN5, and β-actin using the corresponding specific antibodies. (b) Quantification of 
IκB-α, normalized to β-actin. The graph represents means±range/2 of 2 independent experiments (c) 
Immunodetection of IκB-α, CSN5, and β-actin in cell lysates of HUVECs treated with TNF-α for the 
indicated time points. (d) NF-κB-dependent luciferase activity after normalization to β-galactosidase 
activity, relative to the untreated control. Data represent means±SEM of 4 independent experiments. 
Two-way ANOVA with Bonferoni post-test for comparison of control versus CTAP-CSN5: **p<0.01. 
Two-tailed t-test for comparison versus unstimulated cells: #p<0.05. 
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4.3 Endogenous interaction between the CSN and the IKK complex 
The observation that CSN5 inhibits NF-κB activation in TNFα-stimulated ECs, set the 
stage to pursue a possible interaction between the CSN and the IKK complex, which 
is immediately upstream of ΙκB-α. The presence of a CSN complex in HUVECs was 
examined by coimmunoprecipitation (CoIP) of CSN3 and CSN5, confirming their 
interaction at the endogenous level (Figure 20a). Furthermore, immunoprecipitation 
of endogenous IKK1 and IKK2 from TNFα-stimulated HUVECs resulted in a 
coprecipitation of endogenous CSN3 and CSN5 (Figure 20b). Inversely, endogenous 
IKK2 was found to coprecipitate with CSN5 (Figure 20c). In addition, the interaction 
between the CSN and the IKK complex was revealed to be sensitive to TNF-α 
stimulation. Coprecipitation of IKK2 and CSN5 was maximal in unstimulated 
HUVECs and decreased upon TNF-α exposure in a time-dependent manner (Figure 
20d). In addition, a semi-endogenous immunoprecipitation revealed interaction of 
CSN2 with the regulatory subunit of IKK, IKKγ (NEMO) (Figure 20e)          
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Figure 20 Interaction between CSN and IKK complexes in HUVECs. (a) Immunoprecipitation of 
endogenous CSN5 and CSN3 from TNF-α-stimulated HUVECs (30 min), followed by immunodetection 
for CSN3 and CSN5 in immunoprecipitates (IP) and input as indicated. (b) Immunoprecipitation of 
endogenous IKK1 and IKK2 from TNF-α-stimulated HUVECs (30 min), followed by immunodetection 
for IKK2, CSN3 and CSN5 in immunoprecipitates (IP) and input as indicated. (c) Immunoprecipitation 
of endogenous CSN5 from TNF-α-stimulated HUVECs (30 min), followed by immunodetection for 
IKK2 in immunoprecipitate (IP) and input as indicated. (d) HUVECs were treated with TNF-α for 
different time periods, followed by immunoprecipitation of endogenous CSN5 and immunoblotting for 
IKK2 and CSN5. A representative immunoblot is shown (left). The graph (right) represents the 
quantification of immunoprecipitated IKK2 after normalization to immunoprecipitated CSN5. The graph 
represents means of 2-3 independent experiments, and the range/2 (for n=2) or SEM (for n=3). (e) 
HUVECs were transiently transfected with Flag-CSN2 expression construct and treated with TNF-α for 
30 min followed by immunoprecipitation of Flag-CSN2 and immunodetection of IKKγ/NEMO using 
their specific antibodies. (a-e) Immunoprecipitation with an isotype antibody (IgG) was used as 
negative control. 
 
4.4 CSN attenuates the activation of IKK in TNF-α-stimulated endothelial cells 
Interaction of proteins often leads to one protein exerting its effect on the binding 
partner which subsequently reflects on the biological functions in which they 
participate. The urge to pursue the effect of CSN on the activation of IKK was 
induced by the observation that CSN interacts with IKK (Figure 20) and that, 
silencing the gene expression for CSN5 leads to enhanced NF-κB activation (Figure 
18e). It was therefore speculated that, inactivation of CSN might influence the activity 
of IKK. To verify this hypothesis, CSN was depleted from HUVECs through siRNA 
technology that targeted either CSN2 or CSN5. Knockdown efficiency here was 
similar to that in Figure 1. Enhanced phosphorylation of IKK was observed after 
challenging the cells with TNF-α (Figure 21). Importantly, this enhanced 
phosphorylation stayed up to 60 min in CSN5 knockdown cells (Figure 21) indicating 
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prolonged activation when CSN5 levels in the cells were reduced. This is in line with 
enhanced degradation of IκB-α when CSN5 levels is depleted (Figure 18 b-c). 
 
              
Figure 21 TNFα-induced phosphorylation of IKK is prolonged by CSN2 and CSN5 siRNA. HUVECs 
were transiently transfected with CSN2 or CSN5 siRNA and a scrambled RNA was used as a control. 
96 h after transfection, cells were stimulated for different time intervals and harvested for Western blot 
analysis. Upper, middle and lower panels show immunodetection of P-IKK1/2, IKK2, and β-actin levels 
respectively using corresponding specific antibodies.  
 
4.5 CSN5 depletion triggers the expression of key atherogenic chemokines and 
adhesion molecules in inflamed endothelial cells 
In response to inflammatory and atherogenic stimuli, including TNF-α, the 
transcription factor NF-κB has been shown to up-regulate the expression of 
chemokines such as CCL2 and adhesion molecules such as ICAM-1, VCAM-1, and 
P-selectin, all strongly implicated in atherogenesis192-195, 281. The observation that 
CSN5 knock-down results in an enhanced activation of NF-κB (Figure 18d), 
prompted us to examine its effect on NF-κB-dependent atherogenic gene expression.  
Although CSN5 silencing in HUVECs did not significantly affect the basal levels of 
NF-κB-dependent target genes (Figure 22a), TNFα-triggered transcription of CCL2, 
ICAM-1 and VCAM-1 was markedly enhanced upon CSN5 knock-down (Figure 22b-
d). Also the cell surface protein expression of ICAM-1 and P-selectin was markedly 
increased in TNFα-stimulated HUVECs upon CSN5 depletion (Figure 22e-f). 
Together, these data indicate that CSN5 knock-down upregulates the expression of 
atherogenic, NF-κB-dependent genes in inflamed endothelium.  
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Figure 22 CSN5 depletion in ECs upregulates the expression of NF-κB-dependent atherogenic 
chemokines and adhesion molecules upon TNF-α stimulation. HUVECs were transiently transfected 
with CSN5 siRNA or scrambled control siRNA. After 72-96 h, cells were stimulated with TNF-α for 
indicated time periods. (a-d) Real time RT-PCR analysis of CSN5, CCL2, ICAM-1, and VCAM-1 
mRNA levels after normalization to GAPDH. Shown is (a) the means±SEM of 5-6 independent 
experiments and (b-d) one representative experiment of three performed. (e-f) Flow cytometric 
analysis of ICAM-1 and P-selectin. MFI, mean fluorescence intensity. Data represent means±SEM of 
3-4 independent experiments. Two-way ANOVA with Bonferoni post-test for comparison of control 
versus CSN5 siRNA: **p<0.01. Two-tailed t-test for comparison versus unstimulated cells: #p<0.05; 
##p<0.01; ###p<0.001. 
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4.6 Endothelial CSN5 impairs monocyte arrest on TNF-α-stimulated endothelial 
cells  
Adhesion molecules act in synergy with chemokines to trigger the binding and arrest 
of monocytes on activated endothelium, a key step in atherogenesis33. To 
corroborate the finding that CSN5 knock-down increases TNF-α-induced adhesion 
molecule expression (Figure 22) and more importantly, to ask whether an endothelial 
knockdown of CSN5 would lead to altered monocyte adhesion rates, laminar flow 
adhesion assays were performed to investigate the arrest of perfused THP1 
monocytes on resting and TNF-α-stimulated HUVECs. As expected, TNF-α 
administration significantly enhanced THP1 adhesion to HUVECs. Of note, this effect 
was significantly increased upon CSN5 knock-down (Figure 23), while resting 
HUVECs only showed a small, non-significant increase in THP1 adhesion when 
CSN5 was silenced (Figure 23). These results show that an endothelial CSN5 knock-
down functionally translates into an increased monocyte arrest rate on inflamed 
endothelium, indicating that endothelial CSN5 counteracts atherogenic leukocyte 
recruitment processes.   
                                  
Figure 23 TNF-α-triggered mononuclear cell arrest on HUVECs is enhanced by the depletion of 
CSN5. HUVECs were transiently transfected with CSN5 siRNA or scrambled control siRNA. After 72 
h, cells were stimulated with TNF-α for indicated time periods and perfused with calcein-AM-labeled 
THP1 monocytic cells. THP1 adhesion was quantified as previously established9 and is expressed as 
% of the 24 h TNF-α-stimulated control. Data represent means of 2-3 independent experiments, with 
the range/2 (for n=2; 48 h) or SEM (for n=3, 24 h). Two-way ANOVA with Bonferoni post-test for 
comparison of control versus CSN5 siRNA: *p<0.05. One-way ANOVA with Newman-Keuls post-test 
for comparison versus unstimulated cells: ##p<0.01. 
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4.7 CSN5 is upregulated in human atherosclerotic lesions 
Data in Figure 23 indicate that endothelial CSN5 can impair monocyte adhesion to 
ECs under pro-atherogenic conditions. This is the first functional piece of evidence 
suggesting that CSN5 could play a role in atherogenesis. Thus, CSN5 expression in 
human healthy and atherosclerotic carotid arteries was examined. As shown in 
Figure 24a, only a very weak CSN5 staining was visible in the endothelial cell layer of 
healthy carotid arteries. However, a clear CSN5 expression was detected in diseased 
specimens, and increased in the endothelium as well as in macrophage foam cells 
upon atheroprogression. Immunofluorescent colocalization of CSN5 with the 
endothelial cell marker CD31 further confirms endothelial expression in advanced 
plaques (Figure 24b, upper panel). Interestingly, also the CSN subunits CSN8 and 
CSN1 were found to be markedly expressed in atherogenic vessels and to colocalize 
with CD31 (Figure 24b, middle and lower panel). Together, these results suggest an 
active role for CSN5 and the entire CSN complex in the endothelial cell layer of 
atherosclerotic lesions. 
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Figure 24 Expression of CSN in human carotid artery atherosclerotic lesions. (a) 
Immunohistochemical staining with alkaline phosphatase enzyme development of CSN5 in human 
healthy vessels or early and advanced atherosclerotic plaques. Specificity is shown by isotype 
negative control staining. Cell nuclei were counterstained by Mayer’s hemalaun; scale bars 100 µm. 
(b) Double-immunofluorescent colocalization staining of CSN5 (upper panel, green), CSN8 (middle 
panel, green) and CSN1 (lower panel, green) with CD31 (red) in advanced human plaque tissue 
specimens. Cell nuclei were stained with DAPI. Scale bars: 50 µm.  
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4.8 Macrophage-specific deletion of Csn5 via the Cre/loxP recombination 
system 
To corroborate the findings that CSN5 has an active role in atherogenesis, a 
macrophage-specific deletion of Csn5 in mice was generated with the help of the 
Cre/loxP system (Figure 25a). These mice were cross-bred with Apoe−/− mice and 
cells isolated from the bone marrow. The efficiency of in vitro differentiation of 
committed myeloid progenitor cells into macrophage lineage was assessed by F4/80 
surface antigen (Figure 25b). Analysis of mRNA (Figure 25c), genomic DNA (Figure 
25d) and protein levels (Figure 25e) of Csn5 in bone marrow-derived macrophages 
confirmed the deletion of Csn5.  
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Figure 25 Targeted deletion of the Csn5 gene in murine macrophages. (a) Strategy for targeting of 
exon II of the mouse Csn5 locus with loxP sites. The targeting vector was designed to generate, after 
homologous recombination, the targeted Csn5 allele with floxed (LoxP) exon II and the 
Phoshoglucokinase gene (PGK)-neomycin (PGK-neo) cassette flanked by FLP recognition target (Frt) 
sites. Generation of the floxed allele was achieved by removing the neo cassette through crossing with 
FLPe deleter mice. LysMCre-mediated deletion of the floxed allele led to out-of-frame rejoining and 
resulted in the deleted allele. Indicated are the positions and orientation of primers used to detect 
various alleles. (b) Bone marrow cells were isolated and differentiated into macrophages. The 
histogram shows flow cytometric analysis of the surface antigen F4/80 (red) and IgG control (green). 
(c-e) Genomic DNA and RNA were isolated from bone marrow-derived macrophages. The graphs 
represent real time RT-PCR analysis of RNA (c), genomic DNA (d) and protein levels of Csn5. Shown 
in the right panel of (d) are the PCR products of genomic DNA from Csn5 floxed (flox/flox), Csn5 
deleted (del/del) mice, run on a gel. Indicated is the size of the wild type (wt) gene. 
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4.9 Csn5 deletion in macrophages exacerbates atherosclerosis 
CSN5 triggers an enhanced adhesion of monocytes to ECs under pro-atherogenic 
conditions (Figure 23) and is highly expressed in human atherosclerotic carotid 
arteries. This was observed particularly in the endothelium as well as in macrophage 
foam cells upon atheroprogression (Figure 24a-b), prompting us to speculate that 
CSN5 might have a role in atherosclerosis. To test the hypothesis that Csn5 has a 
functional role in murine atherosclerosis in vivo, Csn5−/−/Apoe−/− and Csn5+/+/Apoe−/− 
littermates were fed a high fat diet (HFD) for 12 weeks. All mice appeared healthy, 
reproduced according to Mendelian ratios, and had a normal life span without any 
obvious abnormalities. There was no difference in the leukocyte, erythrocyte, 
thrombocyte counts and weight of the mouse groups used for the study (Figure 26a-
b). Plaque analysis revealed that Csn5-deficient mice had significantly larger 
atherosclerotic plaques in the thoracoabdominal aorta and also in the aortic roots 
(Figure 26 c-d) when compared with control mice on HFD. This finding clearly 
confirmed the anti-atherogenic property of CSN5 as indicated by my in vitro data (see 
Figures 17-24).  
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Figure 26 Macrophage-specific deletion of Csn5 accelerates murine atherosclerosis. (a) Differential 
blood analysis revealed that, leukocyte, erythrocyte and thrombocyte population did not differ between 
Csn5-deficient and control mice. (b) Weight of mouse groups taken at the time of sacrifice. (c-d) 
Csn5−/−/Apoe−/− and Csn5+/+/Apoe−/− mice consumed HFD for 12 weeks and oil red O (ORO)-stained 
intimal lesion size in thoracoabdominal aorta (c) as well as aortic root (d) were quantified. Individual 
data points represent the average of plaque areas per mouse aortic root or thoracoabdominal aorta; 
horizontal bars denote mean. Representative images of the aortic root are shown. Two-tailed unpaired 
t-test with Welch’s corrections for comparison versus control mice: *p<0.05.  
 
 
 
 
Csn5+/+/Apoe−/− Csn5−/−/Apoe−/− 
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5 DISCUSSION 
5.1 CSN5 controls the deneddylation of cullins in endothelial cells  
The CSN complex has an established role in regulating the activity of CRL E3 
ubiquitin ligases by deneddylation of the cullin subunit. This activity has been 
associated with the dissociation of CRLs, maintaining a dynamic activation cycle 
through transient disassembly and assembly of CRL subunits222, 223. Being the only 
component with known catalytic activity, cullin deneddylation has been assigned to 
the JAMM motif of CSN5, which harbors an intrinsic metallo-isopeptidase activity200. 
In line with this, this study demonstrates that silencing of CSN5 in ECs increases the 
CUL1 neddylation level (Figure 17), confirming earlier findings in other cell types237, 
238, 242, 274
. Also, CSN2 knock-down enhanced CUL1 neddylation concomitant with a 
decrease in CSN5 expression. The reduction in CSN5 levels upon CSN2 silencing 
can be explained by the destabilization of the CSN holo-complex upon depletion of 
CSN subunits, resulting in decreased levels of all other CSN members242, 282, 283. 
However, CSN5 can also stably exist independently of the holo-complex, i.e. as 
monomer or in small complexes, and performs important biological functions as 
such222. It was shown that CSN5 silencing can completely abolish CSN5 
monomers237, while in most reports only moderately influencing the stability of the 
other CSN subunits236, 238, 240 and the CSN holo-complex238, 282 indicating that the 
CSN complex-bound form of CSN5 might be more stable. Inversely, transiently 
overexpressed CSN5 was reported to mostly exist as a monomer or in small 
complexes, although tagged CSN5 fusion proteins were demonstrated to be 
incorporable into the CSN complex252, 284, 285. Taken together, these observations 
indicate that it might be difficult to attribute effects of modulating CSN5 expression 
clearly to monomeric CSN5 or the complexes to which it binds. It is expected that 
CSN5 equilibrates dynamically between these different forms and that the gene 
suppression of CSN5 may also lead to reduced levels of the CSN complex at least 
after prolonged periods of time.  
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5.2 CSN5 inhibits NF-κB pathway in TNF-α-stimulated endothelial cells 
IκB-α is a known substrate of the SCFβTrCP-CRL, and its ubiquitination and 
proteasomal degradation triggered by a multitude of inflammatory stimuli is required 
to release the NF-κB dimer for gene transcription226. This study shows that CSN5 
depletion enhances IκB-α degradation upon TNFα stimulation of ECs (Figure 18b-c), 
whereas transient overexpression of CSN5 delays IκB-α turnover (Figure 19c). 
Steady-state levels of IκB-α were similarly affected, showing a reduced or increased 
IκB-α protein level upon CSN5 silencing or overexpression, respectively, supporting a 
role for CSN5 in IκB-α stabilization. Comparable results were obtained in CSN5-
deficient thymocytes, demonstrating markedly decreased steady-state levels of IκB-α 
compared to wild-type cells274. And although CSN2- and CSN5 knock-down 
increased basal IκB-α protein concentrations in HeLa cells, the reduced re-
accumulation of IκB-α upon TNFα stimulation was similarly associated with a 
stabilizing function of the CSN towards de novo-synthesized IκB-α242. Whereas 
Nedd8 conjugation is required for an optimal ubiquitin ligase activity of protein-
destabilizing CRLs227-230, CUL1 deneddylation has been linked with CRL 
dissociation223 and with reduced CRL activity in vitro231, 232. On the other hand, CUL 
deneddylation protects CRL components from self-destruction triggered by excess 
auto-ubiquination-induced degradation223, 234-237, as it supports a dynamic 
disassembly of old, ubiquitinated CRL complexes and the reassembly with fresh 
subunits222, 223. This explains the counter-intuitive observation that, complete CSN 
inactivation decreases CRL activity in vivo233-238 despite enhanced CUL 
neddylation223, 233, 237. In general, CSN5 and the CSN complex might regulate IκB-α 
by several mechanisms: first, the deneddylase activity of CSN might reduce the 
stability and activity of the SCF complex promoting polyubiquitination of IκB-α. A 
reduction of CSN5 would thereby lead to a destabilization of IκB-α (Figure 18). 
Second, there might be an alternative mechanism of IκB-α protection by CSN, 
involving the CSN- associated deubiquitinase USP15, as shown by Schweitzer and 
colleagues242. In 293 cells, stable siRNA-knockdown of CSN5 protected the cells 
from apoptosis induced by TNF-α or serum starvation. This implies that the enhanced 
NF-κB activity achieved after silencing CSN5 gene induces the expression of target 
genes that improve cell survival under stress conditions271.  
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5.3 CSN endogenously interacts with IKKs and attenuates IKK phosphorylation 
The IKK complex has previously been shown to bind CSN5, and TNFα-triggered 
phosphorylation of CSN5 by IKK2 preceded their dissociation, suggested to be 
required for a rapid ubiquitination and degradation of IκB-α271. This transient 
interaction of IKK2 and CSN5 was confirmed in ECs, reaching a minimum upon 30 
min of TNF-α administration (Figure 20). This interaction between the CSN and IKK 
complexes in endothelial cells was found to favor the stability of IκB-α as silencing 
CSN5 and also CSN2 led to enhanced and prolonged phosphorylation of IKKα/β at 
serine 176/180 and therefore activation of IKK complex (Figure 21). An active IKK 
would phosphorylate IκB-α thereby mediating the degradation of IκB-α. This 
observation is in line with the finding that silencing CSN5 or CSN2 enhances the 
degradation of IκB-α (Figure 18). Inactivation of the IKK complex by CSN5 could thus 
provide an additional mechanism underlying the observed IκB-α destabilization upon 
CSN5 silencing. To investigate the relative importance of this mechanism, the effect 
of an IKK phosphorylation-defective CSN5 mutant on TNFα-triggered IκB-α 
degradation could be examined, but this first requires the identification of the 
phospho-acceptor sites in CSN5. Additionally, the activation of IKK in the canonical 
pathway is initiated by K63-linked polyubiquitination of IKKγ/NEMO which functions 
as a binding site for other signaling molecules like TAK1 required for activation of 
IKKβ103-105. The observation that CSN5 and CSN2, and hence the CSN complex 
controls CRL E3 ubiquitin ligases by deneddylation of the cullin subunit, places CSN5 
in a position to control the polyubiquitination of IKKγ/NEMO by a possible 
depolymerization of the polyubiquitin chains. This will impair the activation of TAK1 
and affect the activity of IKK which may explain the observation that silencing CSN5 
or CSN2 results in an increased activity of IKK.  
 
 
5.4 CSN5 inhibits the expression of key atherogenic chemokines and adhesion 
molecules and impairs monocyte arrest on TNFα-stimulated ECs 
In accordance with the observed effects on basal and TNF-α-induced IκB-α levels, 
transient overexpression of CSN5 significantly reduced NF-κB-dependent 
transcription (Figure 19d), while CSN5-silenced ECs displayed a marked increase in 
NF-κB transcriptional activity (Figure 18d). The latter corresponded with an increased 
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expression of NF-κB-dependent target genes, both at the RNA as well as protein 
level (Figure 21). Furthermore, the enhanced cell surface presentation of the 
adhesion molecules ICAM-1 and P-selectin on TNF-α-stimulated ECs upon CSN5 
silencing was associated with a significantly increased ability to trigger the arrest of 
perfused THP1 monocytes (Figure 22). Although knock-down of CSN5 also markedly 
enhanced the expression of these adhesion molecules in steady-state, their basal 
levels remained well below the concentrations reached in conditions of TNFα 
administration, which can explain the absence of a significant effect on steady-state 
THP1 binding by ECs upon silencing of CSN5. Mononuclear cell adhesion to 
inflamed endothelium is a crucial step in atherogenesis, as it precedes 
transendothelial migration and accumulation of inflammatory cells in the intima of 
atherosclerotic lesions. Thus, the observation that CSN5 acts as a negative regulator 
of mononuclear cell adhesion to inflamed endothelium by keeping endothelial NF-κB 
activation in check, suggests that endothelial CSN5 exhibits anti-atherogenic 
functions.  
 
5.5 CSN5 is upregulated in human atherosclerotic lesions and reduces murine 
atherosclerosis  
Immunohistochemistry experiments verified that CSN5 is expressed in the 
endothelial cell layer of human early atherosclerotic plaques. Importantly, we found 
that endothelial CSN5 expression was further increased upon atheroprogression. 
Advanced lesions also displayed intense staining in macrophage foam cells, 
confirming earlier findings286. However, whether CSN5 plays a similar role in NF-κB 
attenuation in macrophages remains to be investigated. In addition, NF-κB inhibition 
in macrophages may well have an outcome on atherogenesis that is different from 
the outcome of the endothelial NF-κB blockade. This is indicated by the observation 
that deletion of IKKγ or overexpression of a dominant-negative ΙκB-α protein 
specifically in ECs, reduced atherosclerotic plaque formation in Apoe–/– mice287, while 
a macrophage-specific deficiency of IKK2 resulted in increased atherosclerosis in 
Ldlr –/– mice, predominantly by a reduction in anti-inflammatory gene expression and 
cell survival188. Although deletion of CSN5 in macrophages led to an increased 
atherosclerotic plaque, whether NF-κB/CSN axis is involved remains elusive. A link 
between CSN5 silencing and enhanced cell survival, likely through increased NF-κB 
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activation, has been observed in stressed 293 cells271. In contrast, CSN5-deficient 
thymocytes show defective cell cycle progression and substantial apoptosis at 
specific developmental stages, which was linked to reduced steady-state NF-κB 
activation combined with increased p53 signaling, shifting the balance from anti- to 
pro-apoptotic gene transcription274. This emphasizes the importance to analyze the 
effect of CSN5 on NF-κB activation in a cell type-specific manner. On the other hand, 
it might be possible that complete deletion of CSN5 has drastically different effects 
than knocking down to low basal expression level. It is conceivable, that a reduction 
of the CSN5 level results in increased NF-κB activation and expression of anti-
apoptotic genes, while complete elimination of CSN5 has the opposite effect (e.g. by 
eliminating the function of CRLs due to a block in the disassembly/re-assembly 
activation cycle).  
 
In addition to regulating NF-κB activation, CSN5 promotes the stabilization (e.g. as 
for HIF-1α) or destabilization (e.g. p27, p53) of several critical cellular regulators222. 
Furthermore, CSN5 has been shown to act as a transcriptional co-activator for AP-
1218 and MYC288, and also binds MIF258, 286, a non-canonical chemokine with 
important pro-atherogenic properties9, 289. Whereas MIF impairs CSN5-mediated 
JNK/AP-1 transcriptional activity258, CSN5 counter-regulates MIF secretion290, also 
supporting an atheroprotective role for CSN5. Thus, it can be speculated that the 
overall outcome of CSN5 on atherosclerosis will be the result of interplay of diverse 
cellular pathways, with both impaired NF-κB activation and reduced MIF secretion 
pointing towards an atheroprotective behavior of CSN5 in ECs. The results presented 
in this study identify endothelial CSN5 to reduce inflammatory responses and 
mononuclear cell arrest by impairing NF-κB activation. This argues that CSN5 
confers atheroprotection in the endothelium. Importantly, this atheroprotective role of 
CSN5 was also observed in a mouse model of atherosclerosis when Csn5 was 
ablated in macrophages. The acceleration of atherosclerosis observed in Csn5-KO 
mice when compared with littermate control confirms the atheroprotective role of 
CSN5. The exact mechanism behind this effect needs to be addressed specifically 
for macrophages with careful extrapolation of the effect seen for CSN5 on ECs to 
macrophages.  
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Besides modulating the activity of NF-κB, CSN5 has also been shown to interact with 
the cytoplasmic domain of LFA-1261, a critical factor in atherogenic leukocyte 
recruitment. Since CSN5 either sensitizes or desensitizes its target proteins towards 
the UPP238, it could be speculated that CSN5 might interfere with the firm adhesion 
and transmigration of leukocytes, a process critical for atherogenesis and controlled 
partly by LFA-1. Intuitively, CSN5 would destabilize LFA-1 leading to impaired 
leukocyte recruitment or block inside out signaling; consequently, deletion of Csn5 in 
a murine model of atherosclerosis may reverse this process leading to accelerated 
atherosclerosis. Also, CSN5 has been shown to interact with ABCA1277, a mediator 
of HDL formation, which acts in concert with ABCG1 to mediate macrophage 
cholesterol efflux. This mechanism protects macrophages against foam cell formation 
and atherosclerosis. Desensitization of ABCA1 towards the UPP by CSN5 might 
result in effective cholesterol efflux and could represent a way of decreasing 
circulating monocytes and a subsequent decrease in atherosclerosis. This is in line 
with exacerbation of atherosclerosis in LysMCre-Csn5/ Apoe–/– mice when compared 
with wild-type littermates. These interplays might contribute to the overall effect of 
CSN5 on atherosclerosis which again might be different for ECs, macrophages and 
SMCs.  
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6 SUMMARY  
The COP9 signalosome (CSN), a multi-functional protein complex involved in the 
regulation of E3 ubiquitin ligases, has been described as a regulator of NF-κB 
signaling, a function assigned to the metalloisopeptidase activity of its subunit CSN5. 
However, its effect on NF-κB activation and pro-atherogenic responses in endothelial 
cells and macrophages and in atherogenesis in vivo remains unknown. This study 
sought to identify a role of the CSN complex and in particular CSN5 in IKK/NF-κB 
signaling in atherogenic endothelial cells in vitro and in murine atherosclerosis in 
vivo. Endothelial cells (ECs) are not just barrier bystanders, but actually determine 
whether immune cells will work within the limits of homeostasis or go overboard into 
autoimmunity and inflammation. As the vascular endothelium plays a pivotal role in 
the inflammatory reactions driving atherosclerosis, the first part of this study focused 
on the role of CSN5 in modulating inflammatory and atherogenic processes in ECs 
through the regulation of NF-κB. By using ECs, this study for the first time 
demonstrates endothelial CSN5 to reduce inflammatory responses and mononuclear 
cell arrest by impairing NF-κB activation, proposing that CSN5 confers 
atheroprotective effects in the endothelium. This was mechanistically shown by co-
immunoprecipitation in human umbilical vein endothelial cells (HUVECs) that 
revealed the presence of a supercomplex between IKK and the CSN, which 
dissociates upon TNFα administration. The CSN was found to attenuate the 
phosphorylation of IKK when cells were treated with siRNAs targeting CSN subunits 
2 and 5. Furthermore, transient overexpression of CSN5 protected IκB-α from 
degradation and reduced NF-κB activation upon TNFα stimulation, whereas silencing 
RNA-mediated CSN5 depletion enhanced TNFα-induced IκB-α degradation and the 
concomitant NF-κB activity in NF-κB binding and luciferase reporter assays. 
Sequentially, NF-κB-dependent expression of chemokines and adhesion molecules 
was upregulated, as measured by real-time PCR and flow cytometry, which 
translated into an increased arrest of perfused monocytes on TNFα-stimulated, 
CSN5-depleted HUVECs. Importantly, double-immunostaining for CSN and CD31 
confirmed the expression of CSN subunits in the endothelial layer of human 
atherosclerotic lesions, and revealed an increased expression of CSN5 upon 
atheroprogression. 
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The second part of this work intended to elucidate the functional role of CSN5 in 
murine atherosclerosis in vivo. Macrophages are key cells not only in acute 
inflammation but also in chronic inflammation as they release a number of cytokines 
and other factors upon activation. Chronic inflammatory processes underlie 
atherosclerosis and macrophages have been shown to be key cells in atherosclerotic 
processes. Employing a macrophage-specific deletion of Csn5 in a murine 
atherosclerosis model, this study identifies Csn5 as a novel player in atherosclerosis. 
Ablation of Csn5 was found to exacerbate murine atherosclerosis, an observation 
that confirms the atheroprotective role of CSN5 demonstrated for the first time in this 
study. The evidence presented in this thesis sets the pace to pursue the functional 
role of CSN5 and the entire CSN complex in atherosclerosis in a broader manner 
including EC- and SMC-specific knockout of Csn5 in vivo by conditional deletion. 
This could also be extended to other Csn subunits and the various proatherogenic 
mouse models.   
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7 Zusammenfassung  
Das COP9 Signalosom (CSN) ist ein multifunktioneller Proteinkomplex, der an der 
Regulation der E3-Ubiquitinligasen beteiligt ist und dem eine regulatorische  Rolle bei 
der NF-KB-Signaltransduktion zugeschrieben wird, der die Metallopeptidase-Aktivität 
seiner Untereinheit CSN5 zugrunde liegt. Dennoch ist der Einfluss des COP9-
Signalosoms auf die NF-κB-Aktivierung und proatherogene Vorgänge sowohl in 
Endothelzellen und Makrophagen  als auch in der Atherogenese in vivo unbekannt. 
Das Ziel dieser Arbeit war, die Rolle des CSN-Komplexes insbesondere CSN5 zu 
untersuchen und seine Beteiligung an der IKK/NF-κB-Signalweg in atherogenen 
Endothelzellen in vitro und in der murinen Atherosklerose in vivo zu identifizieren. 
Endothelzellen (ECs) sind hierbei nicht nur als „Randspieler“ zu betrachten, sondern 
sie bestimmen, ob sich die Aktivität der Immunzellen innerhalb der homöostatischen 
Grenzen bewegt oder ob Autoimmunität und Entzündungsprozesse eingeleitet 
werden. Da das Gefäßendothel eine zentrale Rolle bei den inflammatorischen 
Reaktionen spielt, die die  Atheroskleroseentwicklung  vorantreiben, liegt der Fokus 
des ersten Teils dieser Studie auf der Rolle der CSN5-Untereinheit bei der 
Modulation von entzündlichen und atherogenen Prozessen in ECs durch die NF-κB-
Regulierung. Durch diese Studie konnte zum ersten Mal gezeigt werden, dass 
endothelstämmiges CSN5 zu Entzündungsreaktionen und zum Arrest mononukleärer 
Zellen durch die Hemmung der NF-κB-Aktivierung in ECs reduziert, was den Hinweis 
auf atheroprotektive Effekte im Endothel liefert. Diese Entdeckung konnte ebenfalls 
durch Co-Immunpräzipitationsversuche in menschlichen Nabelvenen-Endothelzellen 
(HUVECs) unterstützt werden, die auf das Vorhandensein eines Superkomplexes 
zwischen IKK und CSN hinweisen, dessen Dissoziation durch TNFα   reguliert wird. 
Ebenso konnte gezeigt werden, dass die Phosphorylierung von IKK herabgesetzt 
wird, wenn Zellen mit CSN2- und CSN5-siRNA  behandelt wurden. Transiente 
Überexpression von CSN5 verhinderte der Abbau von IKB-α und eine Reduktion der 
NF-κB Aktivierung nach TNFα-Stimulation, hingegen CSN5 siRNA förderte der 
Abbau von IKB-α und die damit einhergehende NF-κB-Aktivität in NF-κB-Bindungs- 
und Luciferase-Reporter-Assays. Demzufolge wird die NF-κB-abhängige Expression 
von Chemokinen und Adhäsionsmolekülen hochreguliert, wie auch mittels real-time-
PCR und Durchflusszytometrie gezeigt werden konnte, wobei ein verstärkter 
Zellarrest perfundierter Monozyten auf TNFα-stimulierten und CSN5-armen HUVECs 
festgestellt werden konnte. 
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Die Immundoppelfärbung von CSN und CD31 bestätigte darüber hinaus sowohl die 
Expression der CSN-Untereinheiten in athero-sklerotischen Läsionen der humanen 
Endothelschicht als auch eine erhöhte Expression von CSN5 während der 
Atheroprogression. 
 
Der zweite Teil dieser Arbeit beschäftigt sich damit,  die funktionelle Rolle der CSN5 
in der murinen Atherosklerose in vivo aufzuklären. Makrophagen spielen nicht nur bei 
der akuten Immunabwehr eine wichtige Rolle, aber auch bei chronischen 
Entzündungen, da sie an der Freisetzung einer Reihe von Cytokinen und anderen 
Faktoren beteiligt sind. Sie gelten als Schlüsselzellen in atherosklerotischen 
Prozessen, denen chronische Inflammation zugrunde liegt. In dieser Studie konnte 
mithilfe einer Makrophagen-spezifischen Deletion im Csn5-Gen das CSN5 als neuer 
Spieler im murinen Artherosklerosemodel identifiziert werden. Durch die 
Beobachtung, dass das Fehlen von CSN5 die murine Artherosklerose verschärft, 
konnte die atheroprotektive Funktion des Proteins in dieser Studie zum ersten Mal 
bestätigt werden. Die im Rahmen dieser Arbeit erbrachten Beweise setzen den 
ersten Schritt, die funktionelle Rolle von CSN5 und im weiteren Sinne des gesamten 
CSN-Komplexes in Atherosklerose zu erfassen. Die  in diesem Zusammenhang  
eingesetzten EC-und SMC-spezifischen Csn5-knockouts in vivo mithilfe von 
konditionaler Deletion könnten auch auf andere CSN-Untereinheiten und 
verschiedene proatherogenic Mausmodellen ausgeweitet werden. 
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